

# SERTIFIKAT

Direktorat Jenderal Penguatan Riset dan Pengembangan,  
Kementerian Riset, Teknologi, dan Pendidikan Tinggi



Kutipan dari Keputusan Direktur Jenderal Penguatan Riset dan Pengembangan,  
Kementerian Riset, Teknologi, dan Pendidikan Tinggi Republik Indonesia  
Nomor: 21/E/KPT/2018, Tanggal 9 Juli 2018  
Tentang Hasil Akreditasi Jurnal Ilmiah Periode I Tahun 2018

Nama Jurnal Ilmiah  
**Jurnal Gizi Indonesia (The Indonesian Journal of Nutrition)**

E-ISSN: 2338-3119

Penerbit: Departemen Ilmu Gizi FK UNDIP

Ditetapkan sebagai Jurnal Ilmiah

## TERAKREDITASI PERINGKAT 2

Akreditasi berlaku selama 5 (lima) tahun, yaitu  
Volume 4 Nomor 2 Tahun 2016 sampai Volume 9 Nomor 1 Tahun 2020

Jakarta, 9 Juli 2018  
Direktur Jenderal Penguatan Riset dan Pengembangan

  
Dr. Muhammad Dimiyati  
NIP. 195912171984021001

TERAKREDITASI







**Current issue: Vol 10, No 2 (2022): Juni** (<https://ejournal.undip.ac.id/index.php/jgi/issue/current>) | **Archives** (<https://ejournal.undip.ac.id/index.php/jgi/issue/archive>) | **Start Submission** (<https://ejournal.undip.ac.id/index.php/jgi/about/submissions>) | **Manuscripts must be in English** (<https://ejournal.undip.ac.id/index.php/jgi/announcement/view/161>)

Jurnal Gizi Indonesia (The Indonesian Journal of Nutrition) (e-ISSN: 2338-3119 (<http://issn.pdii.lipi.go.id/issn.cgi?daftar&1368763540&26&8>)) is published twice a year (June and December) by **Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro** (<http://gizi.fk.undip.ac.id/en/>) in collaboration with the **Indonesian Nutrition Association (PERSAGI)** (<https://persagi.org/portals/persagi/>), Central Java. The Indonesia Journal of Nutrition is a National Journal that focused on research in the field of nutrition, with **S2 Sinta Accredited** (<http://sinta2.ristekdikti.go.id/journals/detail?id=2187>). Based on **Kemenristek Dikti Decree No. 148 / M / KPT / 2020** (<https://drive.google.com/file/d/13F-FWFrPnARcsn8czTnBQP4wc2fc7gRk/view?usp=sharing>).

The editor receives unpublished articles from researcher in specific format as mentioned in the "**Author Guideline and Submission** (<https://ejournal.undip.ac.id/index.php/jgi/about/submissions#authorGuidelines>)". The articles will be reviewed by our peer review members based on their expertise.

This journal is protected by copyright law. Reproduction and distribution of the Journal without written permission of the publisher is prohibited.


For JGI journal subscriptions, please fill out the subscription form in the following link : **Subscription Form** (<https://docs.google.com/forms/d/e/1FAIpQLSfHwF5RuvjcFUQb1R2HCeqn6lYkGrCT84IABkX5B8V50qcsMA/viewform?c=0&w=1>)




(<https://www.youtube.com/watch?v=h20XG6uMbhl&t=1s>)



(<https://www.youtube.com/watch?v=i5a9feXUrwU>)



(<https://ejournal.undip.ac.id/index.php/jgi/stats>)



(<https://ejournal.undip.ac.id/index.php/jgi/stats>)

Journal coverage: authors' countries  
Total 626 authors from 7 countries



0.

[Recent articles \(#tabRecent\)](#) [Most cited articles \(#tabCited\)](#) [Contact \(#tabContact\)](#)

## Vol 10, No 2 (2022): Juni

### **Anthropometric Measurements and Inflammatory Marker in Obese Women**

(<https://ejournal.undip.ac.id/index.php/jgi/article/view/36589>)

✉ Kartika Rizky Aulia, Meita Hendrianingtyas, Edward Kurnia Setiawan Limijadi, Dodik Pramono

Citations: 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.10.2.88-94?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.10.2.88-94**  
(<https://doi.org/10.14710/jgi.10.2.88-94>)



PDF

(<https://ejournal.undip.ac.id/index.php/jgi/article/view/36589/21614>)

88-94

### **Provision of Local Food-Based Formula Using Pila Ampullacea, Tempeh, and Moringa Oleifera Leaves to the Acceptability and Nutrition Intake in Hemodialysis Patients**

(<https://ejournal.undip.ac.id/index.php/jgi/article/view/39019>)

✉ Fery Lusviana Widiyanti, Mochammad Sja'bani, Susetyowati Susetyowati, Emy Huriyati

Citations: 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.10.2.95-102?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.10.2.95-102**  
(<https://doi.org/10.14710/jgi.10.2.95-102>)



PDF

(<https://ejournal.undip.ac.id/index.php/jgi/article/view/39019/21581>)

95-102

## User

Username

Password

☐ Remember me

Login

**S2 Sinta Accredited** Based on Ministry of Research, Technology and Higher Education Decree No. 148 / M / KPT / 2020.



## Information for Author

### Focus and Scope

(<https://ejournal.undip.ac.id/index.php/jgi/about/editorialPolicies#focusAndScope>)

### Author Guidelines

(<https://ejournal.undip.ac.id/index.php/jgi/about/submissions#authorGuidelines>)

### Download Manuscript Template

(<https://drive.google.com/file/d/1S98GQEdC7Y7qe2My4gE7e5AS>)

### Download Form of Agreement

([https://drive.google.com/file/d/1WkVfSWi1Np6\\_oZNI0qz1zNu](https://drive.google.com/file/d/1WkVfSWi1Np6_oZNI0qz1zNu))

### Guidelines for Online Submission

(<https://ejournal.undip.ac.id/index.php/jgi/about/editorialPolicies#custom-3>)

### 3)

### Online Submissions

(<https://ejournal.undip.ac.id/index.php/jgi/about/submissions#onlineSubmissions>)

### Printed Journal Subscriptions

(<https://docs.google.com/forms/d/e/1FAIpQLSfHwF5RuvjcFUQb1R2HCeqn6lYkGrCT84IABkX5B8V50qcsMA/viewform?c=0&w=1>)

### Journal Contact

(<https://ejournal.undip.ac.id/index.php/jgi/about/contact>)

## Download JGI Apps on Android now



(<https://drive.google.com/open?>)

id=16pL2vjoQouQwB3yIP13\_cn0mDMF\_2dNX)

## Find Us on Facebook



(<https://www.facebook.com/profile.php?id=100015450430384>)

## Notifications

### • View

(<https://ejournal.undip.ac.id/index.php/jgi/notification>)

### • Subscribe

(<https://ejournal.undip.ac.id/index.php/jgi/notification/subscribe>)

## Journal Content

Search

Search Scope

All

Search

## Browse

### • By Issue

(<https://ejournal.undip.ac.id/index.php/jgi/issue/archive>)

### • By Author

(<https://ejournal.undip.ac.id/index.php/jgi/search/authors>)

### • By Title

(<https://ejournal.undip.ac.id/index.php/jgi/search/titles>)

### • Other Journals

(<https://ejournal.undip.ac.id/index.php/index/search>)





[Home \(https://ejournal.undip.ac.id/index.php/jgi/index/\)](https://ejournal.undip.ac.id/index.php/jgi/index/) / [About the Journal \(https://ejournal.undip.ac.id/index.php/jgi/about/\)](https://ejournal.undip.ac.id/index.php/jgi/about/) / [Editorial Team \(https://ejournal.undip.ac.id/index.php/jgi/about/editorialTeam\)](https://ejournal.undip.ac.id/index.php/jgi/about/editorialTeam)

## Editorial Team

People > [Editorial Team \(https://ejournal.undip.ac.id/index.php/jgi/about/editorialTeam\)](https://ejournal.undip.ac.id/index.php/jgi/about/editorialTeam)  
[Peer-Reviewer \(https://ejournal.undip.ac.id/index.php/jgi/about/displayMembership/399/0\)](https://ejournal.undip.ac.id/index.php/jgi/about/displayMembership/399/0)

### Editor-in-Chief



**Assist. Prof. Ahmad Syaury, S.Gz., M.P.H., Ph.D.** (ScopusID: [57200516331](http://www.scopus.com/authorid/detail.uri?authorid=57200516331) (<http://www.scopus.com/authorid/detail.uri?authorid=57200516331>))  
<http://orcid.org/0000-0002-9552-2834> Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro, Indonesia

### Editorial Board



**Prof. Jeong-hwan Kim** (ScopusID: [56051544900](http://www.scopus.com/authorid/detail.uri?authorid=56051544900) (<http://www.scopus.com/authorid/detail.uri?authorid=56051544900>))  
 Gyeongsang National University, South Korea



**Prof. Ahmad Alkhatib** (ScopusID: [12798864600](http://www.scopus.com/authorid/detail.uri?authorid=12798864600) (<http://www.scopus.com/authorid/detail.uri?authorid=12798864600>))  
 Teesside University, United Kingdom



**Prof. Dr. Irwandi Jaswir, M.Sc.** (ScopusID: [6603028871](http://www.scopus.com/authorid/detail.uri?authorid=6603028871) (<http://www.scopus.com/authorid/detail.uri?authorid=6603028871>))  
 International Islamic University Malaysia, Malaysia



**Assist. Prof. Nattapol Tangsuphoom, Ph.D.** (ScopusID: [57202355008](http://www.scopus.com/authorid/detail.uri?authorid=57202355008) (<http://www.scopus.com/authorid/detail.uri?authorid=57202355008>))  
 Mahidol University, Thailand



**Assist. Prof. Li-Yin (Jessica) Lin, RD., PhD** (ScopusID: [57208385479](http://www.scopus.com/authorid/detail.uri?authorid=57208385479) (<http://www.scopus.com/authorid/detail.uri?authorid=57208385479>))  
 National Taipei University of Nursing and Health Sciences, Taiwan



**Adi Lukas Kurniawan, MS., Ph.D** (ScopusID: [57208399056](http://www.scopus.com/authorid/detail.uri?authorid=57208399056) (<http://www.scopus.com/authorid/detail.uri?authorid=57208399056>))  
 European Molecular Biology Laboratory, Germany



**Prof. dr. Mohammad Sulchan, MSc, DA.Nutr, SpGK(K)** (ScopusID: [56377343600](http://www.scopus.com/authorid/detail.uri?authorid=56377343600) (<http://www.scopus.com/authorid/detail.uri?authorid=56377343600>))  
 Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro, Indonesia



**Martalena Br. Purba, MCN, PhD** (ScopusID: [6603121601](http://www.scopus.com/authorid/detail.uri?authorid=6603121601) (<http://www.scopus.com/authorid/detail.uri?authorid=6603121601>))  
 Department of Health Nutrition, Faculty of Medicine, Gadjah Mada University, Indonesia



**Assist. Prof. Adriyani Pramono, Ph.D** (ScopusID: [56825779200](http://www.scopus.com/authorid/detail.uri?authorid=56825779200) (<http://www.scopus.com/authorid/detail.uri?authorid=56825779200>))  
<https://orcid.org/0000-0003-2159-4576> Diponegoro University, Indonesia



**Dr.-Ing. Dase Hunaefi, S.TP, MFoodST** (ScopusID: [36185421500](http://www.scopus.com/authorid/detail.uri?authorid=36185421500) (<http://www.scopus.com/authorid/detail.uri?authorid=36185421500>))  
 Department of Food Science and Technology, Faculty of Agricultural Technology, Bogor Agricultural University, Indonesia



**Assoc. Prof. Dr. Diana Nur Afifah, S.TP., M.Si.** (ScopusID: [56377075000](http://www.scopus.com/authorid/detail.uri?authorid=56377075000) (<http://www.scopus.com/authorid/detail.uri?authorid=56377075000>))  
<http://orcid.org/0000-0001-8808-1826> Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro, Indonesia



**Assist. Prof. Gemala Anjani, S.P., M.Si., Ph.D.** (ScopusID: [56088545300](http://www.scopus.com/authorid/detail.uri?authorid=56088545300) (<http://www.scopus.com/authorid/detail.uri?authorid=56088545300>))  
 Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro, Indonesia



**Dr. Ali Rosidi, SKM., M.Si.** (ScopusID: [56157390100](http://www.scopus.com/authorid/detail.uri?authorid=56157390100) (<http://www.scopus.com/authorid/detail.uri?authorid=56157390100>))  
 The Indonesian Nutrition Association (PERSAGI) Central Java, Indonesia



**Dr. dr. Mexitalia Setiawati, Sp.A(K)** (ScopusID: [56624601400](http://www.scopus.com/authorid/detail.uri?authorid=56624601400) (<http://www.scopus.com/authorid/detail.uri?authorid=56624601400>))  
 The Dr. Kariadi General Hospital Medical Center of Semarang, Indonesia



**Fitriyono Ayustaningwarno, S.TP., M.Si** (ScopusID: [57201741176](http://www.scopus.com/authorid/detail.uri?authorid=57201741176) (<http://www.scopus.com/authorid/detail.uri?authorid=57201741176>))  
<https://orcid.org/0000-0003-2409-5449> Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro, Indonesia



**Fillah Fithra Dieny, S.Gz., M.Si.** (ScopusID: [57194605388](http://www.scopus.com/authorid/detail.uri?authorid=57194605388) (<http://www.scopus.com/authorid/detail.uri?authorid=57194605388>))  
 Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro, Indonesia

### Managing Editors



**Dewi Marfu'ah Kurniawati, S.Gz., M.Gizi**  
 Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro, Indonesia



**Hartanti Sandi Wijayanti** (ScopusID: [57201187569](http://www.scopus.com/authorid/detail.uri?authorid=57201187569) (<http://www.scopus.com/authorid/detail.uri?authorid=57201187569>))  
 Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro, Indonesia



**Ayu Rahadiyanti, S.Gz, MPH** (ScopusID: [57213823103](http://www.scopus.com/authorid/detail.uri?authorid=57213823103) (<http://www.scopus.com/authorid/detail.uri?authorid=57213823103>))  
<https://orcid.org/0000-0001-5329-6616> Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro, Indonesia



**Mursid Tri Susilo, S. Gz., M. Gizi**  
<https://orcid.org/0000-0002-2809-6310> Department of Nutrition Science, Faculty of Medicine, Universitas Diponegoro, Indonesia

User

Username

Password

☐ Remember me

**S2 Sinta Accredited** Based on Ministry of Research, Technology and Higher Education Decree No. 148 / M / KPT / 2020.



### Information for Author

#### Focus and Scope

</index.php/jgi/about/editorialPolicies#focusAndScope>

#### Author Guidelines

</index.php/jgi/about/submissions#authorGuidelines>

#### Download Manuscript Template

<https://drive.google.com/file/d/1S98GQEdC7Y7qe2My4gE7e5AS>

#### Download Form of Agreement

[https://drive.google.com/file/d/1WkvsSWi1Np6\\_oZNI0gz1zNU](https://drive.google.com/file/d/1WkvsSWi1Np6_oZNI0gz1zNU)

#### Guidelines for Online Submission

</index.php/jgi/about/editorialPolicies#custom-3>

#### Online Submissions

</index.php/jgi/about/submissions#onlineSubmissions>

#### Printed Journal Subscriptions

[https://docs.google.com/forms/d/e/1FAIpQLSFhwf5RuvjcFUQb1f\\_c=0&w=1](https://docs.google.com/forms/d/e/1FAIpQLSFhwf5RuvjcFUQb1f_c=0&w=1)

#### Journal Contact

</index.php/jgi/about/contact>

### Download JGI Apps on Android now



[https://drive.google.com/open?id=16pL2vjoQouQwB3yIP13\\_cn0mDMF\\_2dNX](https://drive.google.com/open?id=16pL2vjoQouQwB3yIP13_cn0mDMF_2dNX)

### Find Us on Facebook



<https://www.facebook.com/profile.php?id=100015450430384>

### Notifications

#### View

<https://ejournal.undip.ac.id/index.php/jgi/notification>

#### Subscribe

<https://ejournal.undip.ac.id/index.php/jgi/notification/subscribe>

### Journal Content

Search

Search Scope

All

### Browse

#### By Issue

<https://ejournal.undip.ac.id/index.php/jgi/issue/archive>

#### By Author

<https://ejournal.undip.ac.id/index.php/jgi/search/authors>

#### By Title

<https://ejournal.undip.ac.id/index.php/jgi/search/titles>

#### Other Journals

<https://ejournal.undip.ac.id/index.php/index/search>





Home (<https://ejournal.undip.ac.id/index.php/jgi/index/>) / Archives (<https://ejournal.undip.ac.id/index.php/jgi/issue/archive/>) / Vol 9, No 2 (2021) (<https://ejournal.undip.ac.id/index.php/jgi/issue/view/3063>)

## Vol 9, No 2 (2021): Juni

### Table of Contents

#### Articles

##### Effect of tomato and red guava juice on blood glucose level in overweight woman

(<https://ejournal.undip.ac.id/index.php/jgi/article/view/26866>)

✉ Aghnia Ilma Izzati, Mohammad Jaelani, Yuwono Setiadi, Enny Rahmawati, Yulianto Yulianto

 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.80-85?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: [10.14710/jgi.9.2.80-85](https://doi.org/10.14710/jgi.9.2.80-85)

(<https://doi.org/10.14710/jgi.9.2.80-85>)

🕒 Received: 2 Dec 2019; Published: 30 Jun 2021.

##### The acute supplementation of combination juice of yellow watermelon (citrullus lanatus thunb.) - plantain (musa paradisiacal var. Sapientum L.) suppress post-exercise blood lactic acid production in rats

(<https://ejournal.undip.ac.id/index.php/jgi/article/view/25785>)

✉ Farida Farida, Hesti Permata Sari, Afina Rachma Sulistyani

 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.73-79?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: [10.14710/jgi.9.2.73-79](https://doi.org/10.14710/jgi.9.2.73-79)


(<https://doi.org/10.14710/jgi.9.2.73-79>)

🕒 Received: 7 Oct 2019; Published: 30 Jun 2021.

##### The implementation of nutrition improvement programs for underweight children, wasting and stunting in the Department of Health, Central Buton district, Southeast Sulawesi

(<https://ejournal.undip.ac.id/index.php/jgi/article/view/27425>)

✉ Nur Wulandari, Ani Margawati, Zen Rahfiludin

 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.86-96?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: [10.14710/jgi.9.2.86-96](https://doi.org/10.14710/jgi.9.2.86-96)


(<https://doi.org/10.14710/jgi.9.2.86-96>)

🕒 Received: 18 Dec 2019; Published: 30 Jun 2021.

##### Profile of nutritional status, energy availability, haemoglobin levels and bone density in santriwati (Islamic female student) with chronic energy deficiency risk

(<https://ejournal.undip.ac.id/index.php/jgi/article/view/28493>)

✉ Fillah Fithra Dieny, A Fahmy Arif Tsani, Umu Faradilla, Ayu Rahadiyanti

 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.97-104?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: [10.14710/jgi.9.2.97-104](https://doi.org/10.14710/jgi.9.2.97-104)

(<https://doi.org/10.14710/jgi.9.2.97-104>)

🕒 Received: 11 Feb 2020; Published: 30 Jun 2021.

#### General information (#issueinfo)

Published: 01-07-2021

Total Articles: 16  
(including Editorial)

Total Authors: 55

#### Total affiliation countries

(#Country)



horses' affiliations

ueAffiliations)

80-85

#### Issues list

> Vol 10, No 2 (2022): Juni

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

> Vol 10, No 1 (2021):

December

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

> Vol 9, No 2 (2021): Juni

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

> Vol 9, No 1 (2020)

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

> Vol 8, No 2 (2020)

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

> Vol 8, No 1 (2019)

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

> Vol 7, No 2 (2019)

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

> Vol 7, No 1 (2018)

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

> Vol 6, No 2 (2018)

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

> Complete issues

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)  
86-96

articles

ter

[ejournal.undip.ac.id/index.php/jgi/issue](https://ejournal.undip.ac.id/index.php/jgi/issue)

terminan

itas kerja pada

anita

[ejournal.undip.ac.id/index.php/jgi/issue](https://ejournal.undip.ac.id/index.php/jgi/issue)

ter

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

> Pengaruh konseling gizi dan

laktasi intensif dan

dukungan suami terhadap

pemberian air susu ibu (asi)

eksklusif sampai umur 1

bulan

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)


> Front Matter

(<https://ejournal.undip.ac.id/index.php/jgi/issue>)

More cited articles


(<https://ejournal.undip.ac.id/index.php/jgi/stats/>)



**Ganyong-kelor snack bar's glycemic index as a diet for diabetics**  PDF  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/28652/19699>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/28652>)

105-110


Diyan Yunanto Setyaji, Fransisca Shinta Maharini

 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.105-110?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.105-110**


(<https://doi.org/10.14710/jgi.9.2.105-110>)

Received: 19 Feb 2020; Published: 30 Jun 2021.

**Household food security and diet quality with chronic energy deficiency among preconception women**  PDF  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/29454/19700>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/29454>)

111-122

Pradita Putri Ramadhani, Fillah Fithra Dieny, Dewi Kurniawati, Hartanti Sandi, Deny Yudi Fitranti, Ayu Rahadiyanti, A. Fahmy Arif Tsani

 1 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.111-122?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.111-122**


(<https://doi.org/10.14710/jgi.9.2.111-122>)

Received: 11 Apr 2020; Published: 30 Jun 2021.

**Correlation between wrist circumference with blood pressure and creatinine level among elderly**  PDF  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/29941/19728>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/29941>)

123-127

Etisa Adi Murbawani, Etika Ratna Noer, Enny Probosari

 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.123-127?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.123-127**


(<https://doi.org/10.14710/jgi.9.2.123-127>)

Received: 5 May 2020; Published: 30 Jun 2021.

**Catfish (Clarias sp.) as an animal protein source to improve serum albumin levels of hemodialysis patients**  PDF  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/30069/19701>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/30069>)

128-135

Fery Lusviana Widiyanti, Ari Tri Astuti

 1 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.128-135?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.128-135**


(<https://doi.org/10.14710/jgi.9.2.128-135>)

Received: 13 May 2020; Published: 30 Jun 2021.

**Effects of mixture powder of black rice (Oryza sativa L indica), red beans (Phaseolus vulgaris L), and moringa leaves (Moringa oleifera L) on blood glucose concentration in hyperglycemic Rats**  PDF  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/31011/19702>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/31011>)

136-143

Lalu Juntra Utama, Suryana Suryana, Anita Christina Sembiring

 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.136-143?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.136-143**


(<https://doi.org/10.14710/jgi.9.2.136-143>)

Received: 19 Jun 2020; Published: 30 Jun 2021.

**The effectiveness of Islamic comic media in increasing the attitude of healthy breakfast among students**  PDF  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/31273/19703>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/31273>)

144-150

Amilia Yuni Damayanti, Joyeti Darni, Hafidzatunnisa Hafidzatunnisa

 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.144-150?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.144-150**

(<https://doi.org/10.14710/jgi.9.2.144-150>)

Received: 29 Jun 2020; Published: 30 Jun 2021.



**Application of the general message of balanced nutrition during the pandemic coronavirus disease 2019 (COVID-19) in Mataram City**  [PDF](https://ejournal.undip.ac.id/index.php/jgi/article/view/31369/19704)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/31369/19704>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/31369>) 151-158

 Luh Putu Prema Wadhani, Nani Ratnaningsih

 Citations 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.151-158?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.151-158**  
(<https://doi.org/10.14710/jgi.9.2.151-158>)

🕒 Received: 3 Jul 2020; Published: 30 Jun 2021.

**Antibacterial potential of red dragon fruit peel yogurt (hylocereus spp.) against bacillus subtilis bacteria in hypercholesterolemic wistar rats**  [PDF](https://ejournal.undip.ac.id/index.php/jgi/article/view/32258/19705)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/32258/19705>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/32258>) 159-165

 Natalia Desy Putriningtyas, Mardiana Mardiana, Widya Hary Cahyati

 Citations 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.159-165?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.159-165**  
(<https://doi.org/10.14710/jgi.9.2.159-165>)

🕒 Received: 15 Aug 2020; Published: 30 Jun 2021.

**Differences in triglyceride levels before and after whey protein intervention in field workers exposed and unexposed to arsenic**  [PDF](https://ejournal.undip.ac.id/index.php/jgi/article/view/32300/19706)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/32300/19706>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/32300>) 166-171

 Eka Putri Rahmadhani, Ani Margawati, Apoina Kartini

 Citations 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.166-171?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.166-171**  
(<https://doi.org/10.14710/jgi.9.2.166-171>)

🕒 Received: 18 Aug 2020; Published: 30 Jun 2021.


**The effect of additional protein, phosphatidylcholine, phosphatidylserine, and inulin on S100 $\beta$  levels of acute ischemic stroke patients at Dr. Kariadi Central Hospital, Semarang**  [PDF](https://ejournal.undip.ac.id/index.php/jgi/article/view/32475/19707)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/32475/19707>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/32475>) 172-183


 Stephani Nesya Renamastika, Endang Mahati, Martha Kartasurya, Dodik Pramukarso, Dwi Pudjonarko, Retnaningsih Retnaningsih


 Citations 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.172-183?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.172-183**  
(<https://doi.org/10.14710/jgi.9.2.172-183>)

🕒 Received: 26 Aug 2020; Published: 30 Jun 2021.

**The effect of addition protein, phosphatidylcholine, phosphatidylserine, and inulin on GFAP levels of acute ischemic stroke patients at Dr. Kariadi Hospital, Semarang**  [PDF](https://ejournal.undip.ac.id/index.php/jgi/article/view/32526/19708)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/32526/19708>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/32526>) 184-197

 Diah Retno Wahyuningrum, Retnaningsih Retnaningsih, Martha Irene Kartasurya

 Citations 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.184-197?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.184-197**  
(<https://doi.org/10.14710/jgi.9.2.184-197>)

🕒 Received: 28 Aug 2020; Published: 30 Jun 2021.

**Collaborative model as a training for increasing village health worker competency about complementary feeding**  [PDF](https://ejournal.undip.ac.id/index.php/jgi/article/view/32588/19710)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/32588/19710>)  
(<https://ejournal.undip.ac.id/index.php/jgi/article/view/32588>) 198-207

 Habibah Abidin, Apoina Kartini, Ani Margawati

 Citations 0 (<https://badge.dimensions.ai/details/doi/10.14710/jgi.9.2.198-207?domain=https://ejournal.undip.ac.id>)

| Language: **EN (#)** | DOI: **10.14710/jgi.9.2.198-207**  
(<https://doi.org/10.14710/jgi.9.2.198-207>)

🕒 Received: 1 Sep 2020; Published: 30 Jun 2021.



## Effect of tomato and red guava juice on blood glucose level in overweight woman

Aghnia Ilma Izzati<sup>1\*</sup>, Mohammad Jaelani<sup>1</sup>, Yuwono Setiadi<sup>1</sup>, Enny Rahmawati<sup>2</sup>, Yulianto<sup>3</sup>

### ABSTRACT

**Background:** Based on the results of Riskesdas 2018 that the prevalence of diabetes mellitus in Indonesia showed an increase from 6.9% to 8.5%. Overweight is closely related to impaired blood glucose, insulin resistance, and decreased insulin secretion. Preventive efforts that have been made using non-pharmacological treatments, such as increasing the intake of fiber and lycopene from fruits.

**Objectives:** This study aimed to determine the effect of tomato juice and guava juice on blood glucose levels in overweight women.

**Materials and Methods:** The study design is a true experiment conducted in 11 subjects in treatment group and 11 subjects in control group. The subject of this study were overweight adult women 45-55 years. Blood sampling was taken in the morning, then glucose levels were measured using the GOD-PAP method (Glucose Para Amino Phenazone). We gave 600 ml of tomato juice and red guava every day for 21 days. To find the effect of juice on fasting blood glucose levels controlled by nutrient intake and physical exercise using the Repeated Measure ANOVA test.

**Results:** In the treatment group, there was a decrease of 3.24 mg/dl in blood glucose levels; while, in the control group, the decrease in blood glucose levels was only 0.26 mg/dl. However, we found no statistically significant differences in both groups.

**Conclusions:** Consumption of tomato juice and red guava reduced fasting blood glucose.

**Keyword:** Blood glucose; Tomato; Red guava; Women; Overweight

### BACKGROUND

At the age of 45, people experience an increased risk of developing diabetes and glucose intolerance due to decreased ability of beta cells to produce insulin whose function is to metabolize glucose<sup>1</sup>. Females are more prone to diabetes due to estrogen. As estrogen decreases, insulin resistance begins to arise which causes an increase in blood glucose<sup>2</sup>. Overweight is closely related to several conditions, including impaired blood glucose, disrupted balance of glucose and insulin, and decreased insulin metabolism. Obesity causes an increase in fatty acids or Free Fatty Acid (FFA) in cells and this could lead to insulin resistance<sup>3</sup>.

People suffering from DM will depend on drugs throughout their life. Anti-hyperglycemia drugs cause side effects such as nausea, weight gain, diarrhea, and bloated stomach which lead to non-adherence medication<sup>4</sup>. Therefore, we need an alternative that does not have side effects, which is by utilizing fruit with a low glycemic index. Fruit is a safe alternative because it is part of the diet.

Tomato contains an active substance called lycopene. Lycopene is an antioxidant whose ability is to resist free radicals. Lycopene can lower blood glucose by reducing insulin resistance, leading to cell tolerance to glucose increases, and excess blood sugar levels can be overcome<sup>2</sup>.

Red guava is a fruit with high vitamin C content and pectin-type fiber. Pectin is hypoglycemic which can reduce blood glucose levels as pectin plays a role in the formation of gels in the gastrointestinal tract. Vitamin C plays a role in reducing glucose toxicity, thereby preventing a decrease in  $\beta$  cell mass and insulin level.

In this research, 300 grams of tomatoes and 300 grams of red guavas were processed into juice. This combination is expected to reduce blood glucose levels in overweight females aged 45 - 55 years.

### MATERIALS AND METHODS

This research implemented a true experimental design with randomized pre-test and

<sup>1</sup>Nutrition Major Health Polytechnic of Semarang.

<sup>2</sup>Regional Public Hospital of KRMT Wongsonegoro, Semarang

<sup>3</sup>Regional Public Hospital of dr. Loekmono Hadi, Kudus

\*Correspondence: e-mail: [aghnailma23@gmail.com](mailto:aghnailma23@gmail.com), Telp/HP. 087802828703



## The acute supplementation of combination juice of yellow watermelon (*citrullus lanatus thunb.*) - plantain (*musa paradisiacal* var. *Sapientum l.*) suppress post-exercise blood lactic acid production in rats

Farida\*, Hesti Permata Sari, Afina Rachma Sulistyning

### ABSTRACT

**Background:** Yellow watermelon contains citrulline, which can suppress lactic acid production, while plantains contain potassium which is important for muscle performance. The yellow watermelon and plantain combination juice potential to be a natural sports drink that delays muscle fatigue by suppressing lactic acid production after exercise.

**Objectives:** To determine the effect of yellow watermelon-plantain juice on lactic acid in rats after swimming test.

**Materials and Methods:** This true experimental study used a post-test-only with controlled group design. Thirty Sprague Dawley rats, eight-week-old, male, were divided into five groups, namely positive control (C+), negative control (C-), dose 1 (P1), dose 2 (P2), and dose 3 (P3). The C (+) group received no juice and was not tested swimming, the C (-) group received no juice but was tested swimming, P1 received combined juice up to 1.8 g and tested swimming, P2 received combined juice up to 3, 6 g and tested swimming, P3 received combined juice up to 1.8 g with the addition of 0.27 g granulated sugar and tested swimming. The juice is given 30 minutes before the test. The swim test was performed for three minutes; after that, the blood was taken to test the lactic acid levels. The data were analyzed using the one-way ANOVA and the advanced post-hoc with the least significant difference test.

**Results:** The lactic acid levels in C (+), in C (-), P1, P2, and P3 groups after swimming test were 1.38 mMol / L; 7.14 mMol / L; 3.74 mMol / L; 1.66 mMol; and 2.91 mMol/L. There were differences in levels of lactic acid ( $p < 0.05$ ) in each group after the combination juice intervention was given.

**Conclusion:** Combination juice of yellow watermelon-plantain has an effect on lactic acid levels after swimming test. Dose 2 (3.6 g) was the best because it produces the lowest lactic acid after the swimming test.

**Keywords:** Yellow watermelon; Plantain; Lactic acid; Swimming test

### BACKGROUND

Energy metabolism during anaerobic exercise is accentuated exclusively from muscular strength with high explosive power.<sup>1</sup> This process begins with the glucose breakdown process (glycolysis) as well as the glycogen breakdown process (glycogenolysis) and is independent of oxygen availability during ATP (Adenosine Tri Phosphate) formation.<sup>2</sup> Thus, it is important to acknowledge glucose availability in the muscle

since its metabolic advantage is providing speed and strength in a short period.

Low performance in exercise can be caused by lactic acid accumulation which faster than it should be. However, exercising has an unavoidable side effect that is the production of lactic acid, which might induce muscle fatigue. L-citrulline is one of the most popular types of nutritional supplements that are legal ergogenic aids. L-citrulline has beneficial functions such as accelerating metabolite waste removal like lactic

Jurusan Ilmu Gizi, Fakultas Ilmu-ilmu Kesehatan Universitas Jenderal Soedirman Jl. Dr Soeparno, Karangwangkal, Purwokerto, Jawa Tengah 53123, Indonesia

\*Correspondence : e-mail: farida.140991@gmail.com



## Ganyong-kelor snack bar's glycemic index as a diet for diabetics

Diyan Yunanto Setyaji<sup>1\*</sup>, Fransisca Shinta Maharini<sup>2</sup>

### ABSTRACT

**Background:** Lack of insulin or the inability of cells to respond to insulin causes high blood glucose levels or hyperglycemia, a hallmark of diabetes. Consumption of foods with a low glycemic index and high fiber has been shown to provide the same benefits as pharmacological therapy in the control of postprandial hyperglycemia and can prevent the incidence of hypoglycemia in people with diabetes. Ganyong (*Canna edulis*) is a food source of carbohydrates and fiber. Kelor (*Moringa oliefera*) contains protein and some phytochemical compounds which have a hypoglycemic effect.

**Objectives:** The objective of the study was to analyze the glycemic index of ganyong-kelor snack bars as a diet for diabetics.

**Materials and Methods:** Ten respondents fasted for 10 hours and checked their fasting blood glucose levels, then consumed 105 grams of bread as the reference food. Every 30 minutes after eating, the blood glucose levels were checked. In the following week, after fasted, all respondents consumed 157 grams of a ganyong-kelor snack bar and checked their blood glucose levels every 30 minutes.

**Results:** Every 100 grams of ganyong-kelor snack bar contains 230.13 kcal, 31.97 grams of carbohydrates, 9.25 grams of fat, and 4.75 grams of protein. In this study, bread was used as a reference food. If bread was corrected with glucose as a reference food, the glycemic index of the ganyong-kelor snack bar was 38.08. The calculation of the glycemic load used the converted-glycemic index and the total carbohydrates contained in 100 grams of the food. Ganyong-kelor snack bar had a glycemic load value of 12.10.

**Conclusions:** Ganyong-kelor snack bar had good nutritional content and was categorized as food with a low glycemic index. The hypoglycemic effect of the ganyong-kelor snack bar came from its high fiber content. Ganyong-kelor snack bar can be consumed as a healthy snack for diabetic people.

**Keywords:** Ganyong; Canna; Kelor; Moringa; Diabetes

### BACKGROUND

Diabetes mellitus is a chronic condition that occurs as a result of increased levels of glucose in the blood caused by the body's unable to produce sufficient amounts of insulin or the body is unable to use the insulin produced effectively.<sup>1</sup> Lack of insulin or the inability of cells to respond to insulin causes high blood glucose levels, or hyperglycemia, which is a hallmark of diabetes.<sup>2</sup> In 2017 the prevalence of diabetes mellitus globally is 8.8% or around 425 million adults with 85-95% of these cases are type 2 diabetes mellitus and is expected to increase to 9.9% in 2045.<sup>2-4</sup> The prevalence of diabetes mellitus in Indonesia increases rapidly from 5.7% in 2007 to 6.9 % in 2013 to 8.5% in 2018.<sup>5</sup> Diabetes mellitus has a significant economic impact on countries, health systems, and diabetics or families through direct medical costs and job losses and reduced wages.<sup>5</sup>

Modifiable risk factors for type 2 diabetes mellitus include poor diet and nutrition, excess adiposity, low physical activity, prediabetes or impaired glucose tolerance (IGT), smoking habits, and a history of fetal exposure to high blood glucose

during pregnancy.<sup>4</sup> Recent evidence suggests an association between regular exposure to a high glycemic load diet and causing postprandial hyperglycemia.<sup>6-11</sup> Consumption of foods with low glycemic index and high fiber has been shown to provide the same benefits as pharmacological therapy in the control of postprandial hyperglycemia in the medium term and can prevent the incidence of hypoglycemia in people with diabetes.<sup>11-13</sup> This type of diet can improve insulin sensitivity and fat metabolism.<sup>14</sup> This can provide a good choice for diabetics and can reduce health care costs.

Ganyong (*Canna edulis*) is a food source of carbohydrates with a low glycemic index (20.8) and high fiber (8.59%). The starch content of ganyong consists of 25% amylose.<sup>15,16</sup> The protein content of kelor (*Moringa oliefera*) leaves is 35% of the dry weight. Kelor leaves contain some phytochemical compounds such as alkaloids, flavonoids, glycosides, tannins, and steroids, which have a hypoglycemic effect.<sup>17,18</sup> Diabetics must maintain their diet, type, and calorie content in food, especially in those who use insulin secretion-enhancing drug therapy or

<sup>1</sup> Program Studi Sarjana Gizi STIKes Panti Rapih Yogyakarta

Tantular 401, Pringwulung, Condongcatur, Depok, Sleman, D.I. Yogyakarta, Indonesia 55283

<sup>2</sup> Ph.D. candidate in Health Sciences, Lincoln University College, Malaysia

Wisma Lincoln, No. 12-18, Jalan SS 6/12, Petaling Jaya, Selangor Darul Ehsan, Malaysia 47301

\*Correspondence: email: diyansetyaji@stikespantirapih.ac.id, HP: +62822- 374787-90



## Catfish (*Clarias* sp.) as an animal protein source to improve serum albumin levels of hemodialysis patients

Fery Lusviana Widiyana\*, Ari Tri Astuti

### ABSTRACT

**Background:** Hemodialysis patients often experience hypoalbuminemia complications, which occur mainly due to decreased synthesis due to inflammation, lack of protein intake, the fluid status of patients, and losses from the dialysate. Another problem in hemodialysis is malnutrition, with a prevalence between 23–73% globally. Gastrointestinal disorders such as nausea, vomiting, and decreased appetite also often occur in hemodialysis. Therefore, hemodialysis patients need to get nutritional support, which can be given in the form of catfish abon, one of the local Indonesian food.

**Objective:** To determine the effectiveness of the use of catfish as a source of animal protein to improve the albumin levels of hemodialysis patients.

**Materials and Methods:** This was a quasi-experimental study with a pre-post test design. This study involved 34 hemodialysis patients as subjects, with inclusion criteria, were routinely two times a week, aged >18 years, willing to be the subject and follow the research procedures, have albumin levels  $\geq 3.0$  g/dL, and no catfish allergies. Patients with anasarca edema, experiencing complications of diabetes mellitus and malignancy were excluded. The dependent variable was albumin content, while the independent variable was catfish as an animal protein source. Data were analyzed univariate and bivariate by Fisher's Exact test.

**Results:** Fisher's Exact test results on the effectiveness of using catfish as an animal protein source to improve albumin levels of hemodialysis patients showed  $p\text{-value}=0.048$ .

**Conclusion:** The use of catfish as an effective animal protein source significantly affected on improving albumin levels in hemodialysis patients.

**Keywords:** Nutritional support; Catfish (*Clarias* sp.); Albumin levels; Hemodialysis patients.

### BACKGROUND

Chronic kidney disease is a global widespread epidemic disease, which a prevalence rate is 5-15%. The incidence rate of end-stage renal disease patients requiring dialysis is also increasing (1). Basic Health Research in Indonesia shows that the prevalence of chronic kidney disease nationally increased from 0.2% in 2013 to 0.38% in 2018. Province Special Region of Yogyakarta, where the Panembahan Senopati Hospital is located, ranked 12th nationally for the prevalence of chronic kidney disease (2).

Panembahan Senopati Bantul Hospital is a large type B hospital, which obtained a hospital-level plenary accreditation certificate. Panembahan Senopati Bantul Hospital is one of the hospitals that has a Hemodialysis Unit in Bantul Regency. Based


on data from the 2013 Panembahan Senopati Bantul General Hospital annual report, the number of chronic kidney disease patients undergoing hemodialysis is increasing every year. In 2011, the number of routine hemodialysis patients was 111 people, in 2012, it increased to 125 people, in 2013, it became 142 people, and in 2014 it increased again to 144 people. The hemodialysis patient is accommodated in a room (Hemodialysis Unit) with a capacity of 22 beds.

Hemodialysis patients often experience hypoalbuminemia complications, which occur mainly due to decreased synthesis due to inflammation, lack of protein intake, the fluid status of patients, and losses from dialysate (3,4). Another problem that often arises in hemodialysis is malnutrition, with a prevalence between 23–73%

Department of Nutrition, Faculty of Health Science, Universitas Respati Yogyakarta, Yogyakarta, Indonesia

\*Correspondence: e-mail: lusviana86@gmail.com, phone: +6285702024636





KOMITE ETIK PENELITIAN KESEHATAN  
HEALTH RESEARCH ETHICS COMMITTEE  
RSUP DR. KARIADI SEMARANG  
RSUP DR. KARIADI SEMARANG



**KETERANGAN LAYAK ETIK**  
*DESCRIPTION OF ETHICAL APPROVAL*  
**"ETHICAL APPROVAL"**

No.503/EC/KEPK-RSDK/2020

Protokol penelitian yang diusulkan oleh :  
*The research protocol proposed by*

Peneliti utama : DIAH RETNO WAHYUNINGRUM  
*Principal In Investigator*

Nama Institusi : Program Studi Magister Ilmu Gizi FK UNDIP  
*Name of the Institution*

Dengan judul:  
*Title*

**" PENGARUH PENAMBAHAN PROTEIN, FOSFATIDILKOLIN, FOSFATIDILSERIN DAN INULIN TERHADAP KADAR GFAP DAN KELUARAN KLINIS NEUROLOGIS PENDERITA STROKE ISKEMIK AKUT DI RSUP DR.KARIADI SEMARANG"**

*" PENGARUH PENAMBAHAN PROTEIN, FOSFATIDILKOLIN, FOSFATIDILSERIN DAN INULIN TERHADAP KADAR GFAP DAN KELUARAN KLINIS NEUROLOGIS PENDERITA STROKE ISKEMIK AKUT DI RSUP DR.KARIADI SEMARANG "*

Dinyatakan layak etik sesuai 7 (tujuh) Standar WHO 2011, yaitu 1) Nilai Sosial, 2) Nilai Ilmiah, 3) Pemerataan Beban dan Manfaat, 4) Risiko, 5) Bujukan/Eksploitasi, 6) Kerahasiaan dan Privacy, dan 7) Persetujuan Setelah Penjelasan, yang merujuk pada Pedoman CIOMS 2016. Hal ini seperti yang ditunjukkan oleh terpenuhinya indikator setiap standar.

*Declared to be ethically appropriate in accordance to 7 (seven) WHO 2011 Standards, 1) Social Values, 2) Scientific Values, 3) Equitable Assessment and Benefits, 4) Risks, 5) Persuasion/Exploitation, 6) Confidentiality and Privacy, and 7) Informed Consent, referring to the 2016 CIOMS Guidelines. This is as indicated by the fulfillment of the indicators of each standard.*

Pernyataan Laik Etik ini berlaku selama kurun waktu tanggal 14 April 2020 sampai dengan tanggal 14 April 2021.

*This declaration of ethics applies during the period April 14, 2020 until April 14, 2021.*

April 14, 2020  
Professor and Chairperson.

Dr. dr. M. Sofyan Harahap, SpAn.,KNA



# The effect of addition protein, phosphatidylcholine, phosphatidylserine, and inulin on GFAP levels of acute ischemic stroke patients at Dr. Kariadi Hospital, Semarang

*by Martha Irene Kartasurya*

---

**Submission date:** 20-Sep-2022 02:20PM (UTC+0700)

**Submission ID:** 1904365104

**File name:** e\_ischemic\_stroke\_patients\_at\_Dr.\_Kariadi\_Hospital,\_Semarang.pdf (336.93K)

**Word count:** 9180

**Character count:** 48008



## The effect of addition protein, phosphatidylcholine, phosphatidylserine, and inulin on GFAP levels of acute ischemic stroke patients at Dr. Kariadi Hospital, Semarang

Diah Retno Wahyuningrum<sup>1\*</sup>, Retnaningsih<sup>2</sup>, Martha Irene Kartasurya<sup>3</sup>

### ABSTRACT

**Background:** The occurrence of ischemia causes a loss of energy to switch to anaerobic processes resulting in acidosis due to reduced Adenosina Triphosphate (ATP). This condition makes neuron cells apoptotic. Apoptotic of several biochemical substrates in the brain, such as Glial Fibrillary Acidic Protein (GFAP) exit into the circulatory system which is associated with dysbiosis through immunological pathways.

**Objectives:** To determine the effect of 48g enteral formula containing protein, phosphatidylcholine, phosphatidylserine, and inulin on GFAP levels in patients with acute ischemic stroke Dr. Kariadi Hospital.

**Materials and Methods:** This study was done in a single-blind RCT. Eighteen ischemic stroke patients were randomly divided into intervention (9 subjects) and control groups (9 subjects). The intervention group received 69 g of the powdered enteral formula three times a day for seven days. The formula contained protein (15 g), phosphatidylcholine (128 mg), phosphatidylserine (32 mg), and inulin (3 g). The subject who had diabetes mellitus received for 14 days at a dose of 34.5 g per day (7.5 g protein with additions 64mg phosphatidylcholine, 16mg phosphatidylserine, 1.5 g inulin). The control group received the standard enteral formula from the hospital, which contains (11.8 g protein without additions protein, phosphatidylcholine, phosphatidylserine, and inulin). GFAP levels by ELISA method (Enzyme-linked immunosorbent Assay) at pre and post-intervention.

**Results:** There was a trend of decreasing GFAP levels before and after in the intervention group towards a better direction from  $8.6 \pm 4.25$  to  $8.30 \pm 4.9$  compared with the control group which experienced an increasing trend from  $5.4 \pm 1.8$  to  $7.5 \pm 4$ . There was no significant difference in GFAP levels after intervention between groups ( $p = 0.7$ ).

**Conclusions:** The addition of protein, phosphatidylcholine, phosphatidylserine, and inulin had no significant effect on GFAP levels.

**Keyword:** GFAP; Protein; Phosphatidylcholine; Phosphatidylserine; Inulin

### BACKGROUND

Ischemic stroke occurs when blood supply to the brain is interrupted or reduced due to a blockage. The occurrence of ischemia in cells and reduced glucose supply causes an increased glutamate expression. Glucose metabolism later switches to anaerobic processes so that it becomes acidosis due to reduced ATP. This situation prompts apoptosis or the death of nerve cells in the brain. In the event of apoptosis, some biochemical substrates may leave the brain and leak off into the circulatory system. In addition to apoptosis, there could be a reduction of proteins

that play a role in maintaining the integrity of the blood-brain barrier membrane; hence membrane will encounter permeability. This results in GFAP which should be in the brain structure going out into circulatory system.<sup>1-4</sup>

Glial Fibrillary Acidic Protein (GFAP) is one of the intermediate protein families, including vimentin, nestin, and is known as an intermediate filament (IF) which is a group of cell types found in the central nervous system and is responsible for maintaining the structure and migration of astroglia cells. GFAP plays a role in the mitotic process by adjusting the filamentous tissue in

<sup>1</sup> Department of Nutrition Science, Faculty of Medicine, Diponegoro University, Jl. Prof. Soedarto SH, Tembalang, Semarang, Central Java 50275, Indonesia

<sup>2</sup> Department of Neurology, Faculty of Medicine, Diponegoro University, Jl. Dr. Sutomo, Randusari, Semarang, Central Java 50244, Indonesia

<sup>3</sup> Public Health Nutrition Section, Faculty of Public Health, Diponegoro University, Jl. Prof. Soedarto SH, Tembalang, Semarang, Central Java 50275, Indonesia

\*Correspondence : E-mail: diahsiswiyanto@gmail.com Phone: 08112750312



cells. Besides, GFAP also plays a role in neuron astrocyte interactions and communication between cells. Under physiological conditions, GFAP is not actively secreted by cells and is generally undetectable in the blood of healthy individuals. In a moment of brain injury, astroglia responds by producing more GFAP, which in turn will be released into the Central Nervous System (CNS) fluid and blood. GFAP is exclusively produced by astrocytes so that this protein is particularly observed in the brain. Examinations have shown that GFAP is released rapidly in cases of acute ischemic stroke, wherein levels peak within 12 hours of onset and are maintained for up to 72 hours of onset.<sup>5</sup>

A study by Dvorak et al which stated that serum GFAP has taken within 2-6 hours after stroke onset was significant in differentiating hemorrhagic stroke from ischemic stroke. GFAP reaches its highest level within 12 hours of stroke onset.<sup>6</sup> Supported by research by Puspitasari et al which states there is a significant correlation between GFAP serum levels with stroke severity scale after 1 month of stroke onset.<sup>7</sup> This is different from the study conducted by Neila et al, which aims to determine the difference between blood sampling time and serum GFAP levels within 24 hours of onset in patients with ischemic stroke and hemorrhagic stroke, which shows that there was no significant difference in GFAP levels in samples <6 hours, 6-12 hours, and 12-24 hours in ischemic strokes and ICH strokes.<sup>8</sup>

Factors that can influence GFAP include some cellular processes. In general, GFAP has an important role in the regulation between astrocytes and neurons. Changes in GFAP expression can affect synaptic function, interfere with glutamate metabolism, increase the volume of astrocytes that can expand to the surface area of neurons in contact with the astrocyte membrane, and hypoxia.<sup>4</sup>

Thrombolysis or recombinant tissue plasminogen activator (rTPA) may be one of his definitive therapies. However, this therapy cannot be given to all ischemic stroke patients. Given the strictness of criteria such as the time window, the time for rTPA therapy was <3 hours and a range of 3-4.5 hours after symptom onset. If the therapy is not performed according to established guidelines, one may experience a more severe risk, such as bleeding in angioedema, intracranial and gastrointestinal tract.<sup>9</sup> The limitations of the requirement for rTPA have made many pharmacological therapies emerged, such as

neuroprotective therapies in which the addition of phospholipids given in supplement form (citicoline). Some of the most abundant types of phospholipids are phosphatidylcholine and phosphatidylserine. Phosphatidylcholine can improve the biosynthesis of membrane phospholipids which are deteriorated by an increment in free radicals during brain ischemia (neuroprotection). Besides that, the activation of the enzymes that trigger apoptosis in nerve cells will be inhibited by phosphatidylcholine so that it will affect GFAP levels.<sup>10</sup> Research on the effect of giving protein, neuroprotective substances (phosphatidylcholine and phosphatidylserine), and inulin on markers of brain damage, especially GFAP, is still very limited.

Animal studies with the administration of the 20g citoline have the potential to reduce acute brain damage and improve functional recovery, even when given several hours after an ischemic event because the phosphatidylcholine in citoline can increase the biosynthesis of membrane phospholipids degraded by increased free radicals during brain ischemia (neuroprotection). Besides, citoline has been shown to restore mitochondrial ATPase and Na<sup>+</sup> / K<sup>+</sup> ATPase activity to inhibit phospholipase A2 activation which triggers apoptosis of nerve cells.<sup>11,12</sup> so that will affect the levels of GFAP.

A Japanese study was conducted to investigate the effect of phosphatidylserine extracted from soybeans (Soy-PS) on the cognitive function of an elderly group with memory complaints. Oral administration of Soy-PS improves memory function, especially in the elderly with memory complaints. These effects were similarly observed at low doses (100 mg/day) and high doses (300 mg/day).<sup>13</sup>

Fulfillment of protein intake in stroke patients is often given enteral formula with high calories high protein diet which operates to preserve adequate nutritional intake to speed up the recovery period as the enteral formula contains high protein. Dysphagia, unconsciousness (coma), or what is known as enteral feeding is one alternative to meet the nutritional needs of stroke patients by providing nutrients in the form of enteral formula. The protein content in the enteral formula can improve body metabolism through appetite regulation and/or other mechanisms that can control body weight and body composition.<sup>14</sup> Several studies have proven the benefits of enteral formula protein in increasing protein consumption, muscle mass and possibly



increasing body mass index so that it can improve the motor function abilities of patients.<sup>15-17</sup>

Prebiotics is one of the nutrients needed in stroke patients in addition to phospholipids and protein. C<sub>10</sub> type of which is named inulin. Prebiotic bacteria such as Bifidobacteri<sub>10</sub> and Lactobacilli will ferment inulin to produce Short-Chain Fatty Acid (SCFA) and its fermented products in the form of propionate, butyrate, acetic acid, L-lactate, CO<sub>2</sub>, and hydrogen. Directly or indirectly, the gut-brain axis is influenced by SCFA. The blood-brain barrier can be penetrated by SCFA mediated by monocarboxylate transport<sub>1</sub> (MCT) and improves the integrity of the blood-brain barrier by increasing the expression of tight junction proteins. SCFA will improve inflammation in nerves by modulating levels of neurotrophic factors, improving morphology and glial cell function, and strengthening neurogenesis.<sup>18</sup> Previous research conducted<sub>1</sub> by Liu et al explained that administering 10% inulin for 4 weeks can change the composition of the gut microbiota and improve gut function in obese mice.<sup>19</sup> The same thing was done by Chuncai et al which stated that the administration of NAC, inulin, and a combined the<sub>1</sub> by improved cognition in castrated rats. RX-fed rats treated with either the vehicle or testosterone had a significantly increased number of GFAP positive cells. This increment was attenuated by treatment with<sub>2</sub> NAC, inulin, or the combined therapy.<sup>20</sup>

Enteral nutrition has been shown to reduce infectious complications and improve outcomes in patients with severe TBI. Increasing immune cell activity and the integrity of the i<sub>2</sub>estinal barrier, most likely preventing immune dysfunction and bacterial translocation, are<sub>2</sub> the benefits of early feeding, respectively. The nervous system and endocrine changes following enteral feeding can help reduce massive inflammation through vagus nerve-mediated mechanisms. In a jo<sub>2</sub>nal published by Luyer in Bansal et al, it is shown that enteral feeding, especially dietary fat, stimulates the release of cholecystokinin and binds to cholecystokinin receptors which ultimately leads to activation of the efferent vagal system. This activation triggers an increase in acetylcholine at the gut synaptic level and decreases TNF- $\alpha$  production by way of acetylcholine binding to  $\alpha$ -7 nicotinic receptors on macrophages and other immune cells. Therefore, the positive immunologic benefits of

early enteral feeding after TBI may also be a result of decreased inflammatory cytokine production by way of intraluminal feeds inducing vagus nerve activity which can thus affect the effectiveness of GFAP levels.<sup>21</sup>

<sup>8</sup> This study aimed to determine the effect of giving enteral formula containing protein, phosphatidylcholine, phosphatidylserine, and inulin on GFAP levels in ischemic stroke patients. The intervention group received 69 g of the powdered enteral formula containing 15 g of protein, 128 mg of phosphatidylcholine, 32 mg of phosphatidylserine, and 3 g of inulin dissolved in 250 ml of warm water, given three times a day for seven days.

Giving 69 g of powdered enteral formula because it contains high protein [22 g per 100 g in solid form]<sup>22</sup>. The intake of phosphatidylcholine in the enteral formula also covers 60-90% of the daily requirement for phosphatidylcholine for adults and 3x1 enteral formula feeding for 7 days is following the therapeutic dosage for cytolin<sup>23</sup> where the administration of cytolin 2000 mg has a restorative effect.<sup>24</sup> According to the results of the study, it was shown that the administration of enteral nutrition within 7 days could reduce the mortality rate by 5.8% and survive more than the group who started giving nutrition late.<sup>25</sup> Feeding 69 g of enteral formula has been consistent with the therapeutic dose of phosphatidylserine, whereas administration of 100 mg/day of phosphatidylserine has provided improvement.<sup>26</sup> A dose of 0.5 g has been shown to increase the diversity of probiotic bacteria in the gut<sup>27</sup> which will produce short-chain fatty acids, namely SCFA. Inulin in the enteral formula has met the inulin dose for adults, which i<sub>10</sub> 15 g /day and 0.5 g of inulin has been shown to increase the number of probi<sub>10</sub> bacteria in the intestine which will produce short-chain fatty acids such as SCFA. In subjects suffering from diabetes, the treatment was carried out for 14 days at a dose of 34.5 g per day. The control group was given standard enteral formula from the hospital (11.8 g protein).

## <sup>43</sup> MATERIALS AND METHODS

This research is experimental research with a randomized control trial in a single-blind manner where the research subjects do not know what therapy is being obtained. The research subjects were 18 ischemic stroke pa<sub>12</sub>nts aged >18 years, 9 men and 9 women who were divided into the intervention group (9) and the control group (9)



by randomization. This research was conducted for four months (February-May). The sample size was calculated by taking into account the minimum sample size by using the experimental sample size formula for clinical trials with the following formula:\*\*\*\*\*

$$n_1 = n_2 = 2 \left( \frac{(Z_\alpha + Z_\beta) SB}{x_1 - x_2} \right)^2$$

The results of previous studies showed that the level of GFAP in patients with ischemic stroke was 9.46 ng / mL (mean) and the standard deviation was 4.6 ng / mL.<sup>28</sup> The minimum difference considered significant ( $x_1 - x_2$ ) was 5.13 ng / mL.<sup>28</sup> If the error of type I is set at 15% ( $\alpha=0.15$ ) then  $Z_\alpha=1.440$ . The amount of type II error is set at 20% ( $\beta=0.20$ ) then  $Z_\beta=0.842$  and research power is 80%, the sample size calculation is as follows:

$$n = 2 \left( \frac{(1.440 + 0.842) 4.6}{5.13} \right)^2$$

$$= 8.3 \approx 9 \text{ ischemic stroke patients/group}$$

When the sample was selected with the inclusion criteria of ischemic stroke patients with attack onset, not more than 72 hours as evidenced by an MSCT head scan and aged >18 years, and the exclusion criteria for ischemic stroke patients who had a head injury in the last 3 months, subarachnoid hemorrhage, brain tumor, infection of the central nervous system, psychiatric disorders, complications of acute or chronic renal failure, a history of reactions to enteral formula, hematemesis and / hematemesis + melena and those receiving citicoline. The researcher randomized the subjects by dividing the research subjects into the control group or the intervention group. Researchers provided an informed consent sheet for consent to be the study sample to the patient's family.

GFAP levels were checked at the beginning and the end of treatment. Examination of clinical characteristics is carried out by physical examination and a doctor examines neurological examination. The MSCT scan was performed to determine whether the patient had a head injury in the last 3 months, subarachnoid hemorrhage, brain tumor, infection of the central nervous system, psychiatric disorders, patient medical records to determine blood laboratory results (routine hematology, blood sugar, lipid profile) and complications. acute or chronic renal failure,

history of reactions to enteral formula, hematemesis and / hematemesis + melena, and those receiving citicoline. During the study, researchers assessed the daily intake of food consumed by patients using the 24-hour recall method for 7 days. How to determine the patient's nutritional adequacy level through the average intake divided by the patient's requirement then multiplied by 100. The control group was given enteral formula based on the standard RS conventional enteral formula according to the character/comorbid of the ischemic patient (11.8 protein without the addition of phosphatidylcholine, phosphatidylserine, and inulin). The intervention group was given enteral formula containing 15 g of protein, 128 mg of phosphatidylcholine, 32 mg of phosphatidylserine, 3 g of 69 g of powdered enteral formula inulin, each dissolved in 250 ml of warm water and given three times a day for seven days. In the intervention group suffering from diabetes, the treatment was conducted for 14 days at a dose of 34.5 g per day. This provision is differentiated because the enteral formula given contains a high enough glycemic index which will have side effects in diabetes mellitus patients, so the administration will be reduced but it is carried out for a longer period. To avoid any side effects during the intervention, the researchers observed the patients every day.

The blood samples used were whole blood vein samples taken from the median cubital vein. The 6 ml blood sample was taken using a red vacutainer. The blood was then exported to the central laboratory of Dr. Kariadi for centrifuge and stored at  $-20^\circ\text{C}$  until testing. After the serum was successfully collected, the serum was sent to the Faculty of Medicine Undip GAKI laboratory for testing using the ELISA GFAP E-EL-H1888 kit.<sup>8</sup>

This study has received Ethical Clearance approval by the Medical Research Ethics Commission FK UNDIP / RSDK with Number 503/EC / KEPK-RSDK / 2020.

Statistical analysis was performed on a computer using the SPSS<sup>24</sup> for windows version 20.0 program. Bivariate analysis was performed with the  $\chi^2$  test or with the Fisher-Exact test to determine the change ( $\Delta$ ) in serum GFAP levels and the characteristics of the categorized subjects. The result is significant if  $p < 0.05$ . Multivariate analysis on confounding variables (age, sex, hypertension, diabetes mellitus, obesity status, dyslipidemia, history of stroke, rTPA therapy,



duration of intervention, and length of treatment) was carried out if any variables in the bivariate test were found to be different, with  $p < 0.05$  using General Linear Model.




Figure 1. Flow chart of the research from the beginning to the end of the study

## RESULTS

### Characteristics of Research Subjects

In the implementation of the study, 8 out of 26 patients were found to have dropped out or lost to follow-up. Some of the things that caused the drop-out included patients who were not willing to continue the study (5) and died (3).

A total of 18 acute ischemic stroke patients were the subjects in the study. There were no significant differences in the categories of gender, age, BMI, obesity status, hypertension, diabetes mellitus, dyslipidemia, smoking, rTPA therapy, history of stroke, duration of intervention, and length of stay ( $p > 0.05$ ). However, there were differences in the mean age category ( $p = 0.01$ ).

### Average Adequacy Level of Energy, Protein, Fat, Carbohydrates, Phosphatidylcholine, Phosphatidylserine, and Inulin Intake

Table 2 reveals that there is a significant difference in the adequacy of energy, protein, carbohydrate, phosphatidylcholine, phosphatidylserine, and inulin intake ( $p < 0.05$ ). There was no significant difference in the adequacy of fat intake between groups ( $p > 0.05$ ).

### Difference of Mean and Change ( $\Delta$ ) GFAP levels

There was no difference in the mean GFAP level before the study between intervention group  $8.37 \pm 4.25$  and the control group  $5.4 \pm 1.8$  with a value ( $p = 0.08$ ). These results designate that the conditions of the two groups before the intervention are corresponding (homogeneous). In the intervention group, the average GFAP level managed to decrease from  $8.37 \pm 4.25$  to  $8.30 \pm 4.9$ , whereas in the control group, there was an increment from  $5.4 \pm 1.8$  to  $7.5 \pm 4$ . This disparity shows that the intervention given affects even though this difference is not statistically significant ( $p = 0.9$ ). Changes in  $\Delta$  levels of GFAP in the intervention group also tended to decrease  $-0.07 \pm 2.26$  compared to the control group which tended to increase  $2.13 \pm 2.84$  but not statistically significant ( $p > 0.05$ ).



**Table 1. Characteristics of Research Subjects in the Two Research Groups**

Characteristics	Group		p
	Intervention (n=9)	Control (n=9)	
Gender			
a. Male	4 (44.4%)	6 (66.7%)	0.6 <sup>a</sup>
b. Women	5 (55.6%)	3 (44.4%)	
Average age (years)	50.5 ± 14.8	65.5 ± 8.2	0.01 <sup>b</sup>
Age Category (years)			
a. > 60	3 (33.3%)	7 (77.8%)	0.1 <sup>a</sup>
b. <60	6 (66.7%)	2 (22.2%)	
Average BMI	25.2 ± 4	23.8 ± 2.6	0.3 <sup>b</sup>
Obesity (BMI> 25)			
a. Yes	4 (44.4%)	2 (22.2%)	0.6 <sup>a</sup>
b. Not	5 (55.6%)	7 (77.8%)	
Hypertension			
a. Yes	8 (88.9%)	7 (77.8%)	1 <sup>a</sup>
b. Not	1 (11.1%)	2 (22.2%)	
Diabetes mellitus			
a. There is	3 (33.3%)	5 (55.6%)	0.6 <sup>a</sup>
b. Not	6 (66.7%)	4 (44.4%)	
Dyslipidemia			
a. Yes	7 (77.8%)	8 (88.9%)	1 <sup>a</sup>
b. Not	2 (22.2%)	1 (11.1%)	
Smoke			
a. Yes	4 (44.4%)	6 (66.7%)	0.6 <sup>a</sup>
b. Not	5 (55.6%)	3 (33.3%)	
RTPA therapy			
a. Yes	2 (22.2%)	2 (22.2%)	1 <sup>a</sup>
b. Not	7 (77.8%)	7 (77.8%)	
Stroke History			
a. Yes	3 (33.3%)	3 (33.3%)	1 <sup>a</sup>
b. Not	6 (66.7%)	6 (66.7%)	
Duration of Intervention			
a. 7 days	6 (66.7%)	9 (100%)	0.2 <sup>a</sup>
b. 14 days	3 (33.3%)	0 (0%)	
Length of Hospitalization			
a. <7 days	6 (66.7%)	3 (33.3%)	0.3 <sup>a</sup>
b. ≥ 7 days	3 (33.3%)	6 (66.7%)	

<sup>a</sup> Fisher-Exact; <sup>b</sup> Independent T-Test

**Table 2. Adequacy Level of Patient Intake at Research**

Variable (%)	Intervention	Control	p
	Mean ± SD	Mean ± SD	
Energy Adequacy Level	95 ± 18.4	75.7±11.9	0.018 <sup>b</sup>
Protein Adequacy Level	94.1 ± 17.6	69.1±11.7	0.003 <sup>b</sup>
Adequacy Level of Fat	74.3 ± 21.2	75.9±14.8	0.9 <sup>b</sup>
Adequacy Level of Carbohydrates	106.9 ± 20.5	78.8±14.4	0.004 <sup>b</sup>
Adequacy Level of Phosphatidylcholine	72.7±8	25.2±3.4	0.0 <sup>b</sup>
Adequacy Level of Phosphatidylserine	112.3±12.3	49±10.2	0.0 <sup>b</sup>
Adequacy Level of Inulin	92.4±7.9	24.1±7.6	0.0 <sup>b</sup>

<sup>b</sup>Independent T-Test






Figure 2. Average GFAP Levels Between Groups

11

<sup>b</sup>Independent T-Test; <sup>c</sup>Paired T-Test

### Sub-Group Analysis of Inter-Group GFAP Levels

Median GFAP levels before the study in the intervention group DM subgroup 11.3 (2.4 – 62.4) with the control group 6 (3.9 – 8.1) was not statistically significant ( $p = 0.3$ ). These results indicated that the state of the two groups before the intervention was in identical condition. In the DM sub-group in the intervention group, the median GFAP level increased from 11.3 (2.4 – 12.4) to 12.6 (2.1 – 12.8), it was the same as the control group which also increased from 6 (3.9 – 8.1) to 7 (3.4 – 15.6) and statistically, this difference was not significant ( $p > 0.05$ ). In the DM subgroup, the change in GFAP levels in the intervention group also decreased from 0.4 (-0.3 – 1.3) the same was the case with the control group 1 (-0.5 – 7.9) nonetheless, this difference was not statistically significant.

Median GFAP levels before the study in the non-DM subgroup of the intervention group 9.6 (1.1-12.3) with the control group 4.1 (2.8-6.7) were not statistically significant ( $p = 0.1$ ). These results indicated that the condition of the two groups before the intervention is in the same condition. In the non-DM subgroup the intervention group median GFAP level there was a tendency to decrease from 9.6 (1.1-12.3) to 7.3 (0.8-14.2), in contrast to the control group which there was an increase from 4.1 (2.8-6.7) to 5.9 (3.8-8.2), and statistically, this difference was not significant ( $p > 0.05$ ). In the non-DM subgroup, the change in  $\Delta$  GFAP levels in the intervention group also tended to decrease -0.2 (-3.5 – 3.4) is different the case with the control group which there was an increase of 0.8 (-0.5 – 4.9) however, this difference was not statistically significant.

Table 3. Sub-group analysis of GFAP levels between groups

Sub Group	Kelompok	n	Before Median (minimum-maximum)	After Median (minimum-maximum)	p	$\Delta$ Median (minimum-maximum)
DM	Intervention	3	11.3 (2.4 – 12.4)	12.6 (2.1 – 12.8)	0.2 <sup>d</sup>	0.4 (-0.3 – 1.3)
	Control	5	6 (3.9 – 8.1)	7 (3.4 – 15.6)	0.1 <sup>c</sup>	1 (-0.5 – 7.9)
	p		0.3 <sup>b</sup>	0.8 <sup>c</sup>		0.3 <sup>b</sup>
Non DM	Intervention	5	9.6 (1.1-12.3)	7.3 (0.8-14.2)	0.7 <sup>c</sup>	-0.2(-3.5 – 3.4)
	Control	5	4.1 (2.8-6.7)	5.9 (3.8-8.2)	0.2 <sup>c</sup>	0.8 (-0.5 – 4.9)
	p		0.1 <sup>b</sup>	0.4 <sup>b</sup>		0.2 <sup>b</sup>

<sup>b</sup>Independent T-Test; <sup>c</sup>Paired T-Test; <sup>d</sup>Wilcoxon; <sup>e</sup>Mann-Whitney



#### GLM (General Linear Model)

Table 4 shows that there is no significant difference in GFAP levels controlled by the age variable ( $p = 0.3$ )

Table 4. General Linear Model

Variable	Covariate	$p$	$R^2$	Lower	Upper
(Δ) GFAP levels	Age	0.5	0.1	-0.14	0.079

#### DISCUSSION

Subject characteristics data revealed that there were no significant differences in the categories of gender, age, BMI, obesity status, hypertension, diabetes mellitus, dyslipidemia, smoking, rTPA therapy, history of stroke, duration of intervention, and length of stay ( $p > 0.05$ ). However, there were differences in the mean age category ( $p = 0.01$ ). Stroke is often referred to as a disease suffered by older people. Currently, there was a trend that young people suffer from a stroke. The rising number of stroke cases at a young age can be prompted by a not-healthy lifestyle, such as smoking, alcohol consumption, frequent eating low-fiber foods such as fast food or junk food, and lack of exercise which will lead to hypertension. The habit is usually worsened by people in Central Java who are accustomed to consuming sweet foods or high glucose levels and foods containing coconut enteral formula which can trigger atherosclerosis and thrombosis, which results in reduced oxygen supply to the brain and can lead to stroke. The outcomes of the different test results for the adequacy of energy intake, carbohydrate intake, and fat intake between the intervention group and the control group showed significant results ( $p < 0.05$ ) but not for fat intake ( $p > 0.05$ ). The exception is because one of the interventions given to the control group was standard enteral formula from the hospital, where before the 7th day and the patient had gone home, the researchers could not bring the enteral formula to continue therapy at home for one reason or another. Unlike the case with the intervention group before the 7th day; however, the patient had gone home, the researcher could provide the enteral formula to continue therapy at home. It could also be caused by monitoring food consumption before the study was completed. Researchers carry out a recall via cellular media such as WhatsApp because when the study took place coincided with the COVID-19 pandemic, which caused the patient to be unwilling to be

visited by the researcher. If the patient during the study was still in the hospital, there was a standard portion for each type of diet. However, it is different from patients who have not returned home before the 7th day. There is also another possibility, such as when researchers do a recall, patients tend to overestimate or underestimate the food they eat. The size of the household measurement also varies, so it can affect recall results. There is also another possibility, such as when researchers do a recall, patients tend to overestimate or underestimate the food they eat. The size of the household measurement also varies, so it can affect recall results. There is also another possibility, such as when researchers do a recall, the patient tends to overestimate or underestimate the food consumed. The size of the household measurement also varies, so it can affect recall results.

The distribution of serum GFAP levels at the start and end of the study found that all patients were at abnormal levels ( $>0.11$  ng/ml).<sup>7</sup> This could result in the presence of high-fat content or other anomalies in the sample that could prompt a matrix effect, which would interfere with detection. The hemolyzed blood sample contains the HRP analog (Horseradish Peroxidase), which can make a false-positive result. The hemolyzed sample releases a substance from the red blood cells, which can be mistaken for HRP. HRP is the critical reagent used for ELISA. Therefore, once the sample is hemolyzed, detection will be affected. This is one of the factors that can influence GFAP.

Other factors that can affect GFAP occur in several cellular processes. The drastic decrease in oxygen in the brain causes the brain to undergo anaerobic metabolism so that the availability of ATP is low. Hypoxic conditions cause neuron cell death in minutes because the brain is a part that is very sensitive to hypoxic states. Hypoxia triggers a series of pathways that lead to decreased energy and the extracellular release of glutamate. Neurons and glial cells can die through various causes such as excitotoxicity, cellular edema, oxidative stress, and inflammation. Hypoxia increases the formation of reactive oxygen species (ROS) which results in oxidative stress on cells. Increased levels of ROS are a major cause of brain tissue damage after hypoxia. ROS damage tissue directly through the modification of cellular proteins, lipids, and DNA. ROS directly interferes with cellular signaling and the regulation of gene expression. Astrocytes play an



especially important role in the communication between astrocytes-neurons through the release of several neurotrophic factors to maintain central nervous system homeostasis. Astrocytes also play a role in maintaining homeostasis in the environment around neurons. Recent research has shown that astrocytes are immunocompetent in the brain. If there is a disturbance in the brain that causes damage, the astrocytes will be activated and move quickly to the site of damage (astrogliosis). On excessive activation, it turns out that astrocytes increase the production of several substances, one of which is a glial fibrillary acidic protein (GFAP).<sup>29</sup>

Mean baseline GFAP serum levels in the intervention group  $8.37 \pm 4.25$  and control group  $5.4 \pm 1.8$  with a value ( $p = 0.08$ ). The final study serum GFAP levels in the intervention group were  $8.30 \pm 4.9$  and in the control group was  $7.5 \pm 4$ . These numbers showed that the intervention given still affects even though the difference is not statistically significant ( $p = 0.9$ ). In Figure 2, the intervention group declined  $-0.07 \pm 2.26$  compared to the control group, which increased  $2.45 \pm 2.86$ . This difference was statistically significant ( $p = 0.03$ ).

The difference is partly because the patients in the study sample were patients who had repeated strokes (had a history of stroke), which according to the study of Ren *et al.* (2016) which examined GFAP levels in 13 subjects with hemorrhagic strokes, 23 subjects with ischemic strokes and 7 subjects with recurrent stroke reported that in patients with ischemic stroke, the mean serum GFAP level was significantly lower in subjects without a history of stroke compared with patients who had a previous stroke ( $p = 0.004$ ). This increment occurred due to persistent pathophysiological processes including vascular disorders, long-term changes in BBB permeability, and damage to the brain parenchyma itself triggered by an initial stroke.<sup>30</sup> In this study, patients with recurrent strokes found five patients in the control group, three patients in the treated group.

This can then be caused by comorbid patient diseases such as diabetes mellitus. Research conducted by Lotosh *et al.* (2013) on experimental animals by inducing streptozotocin (STZ) showed that autoantibodies against neuron proteins, especially GFAP increased sharply on day five after being induced by streptozotocin. In this study, it can be concluded that STZ produces a

toxic effect on astrocytes which causes the release of GFAP protein into the bloodstream and causes the formation of AAb (autoantibody) which is specific to GFAP protein.<sup>31</sup>

The COVID-19 pandemic can also cause another thing during the research, which resulted in a lack of research samples. Where in a study conducted by Zang *et al.* (2019) which examined the relationship between giving citicoline injection to 102 patients with hemorrhagic stroke and GFAP levels showed a significant relationship ( $p = 0.000$ ).<sup>28</sup>

Another thing is made possible by the dose of enteral formula that is too small, the duration of administration, and the route of administration which can be the cause of the research results. The doses in this study were 45 g protein/day, 384 mg/day phosphatidylcholine, 96 g/day phosphatidylserines, and 9 g/day inulin. In some studies, the minimum duration of intervention given was 14 days and obtained significant results.<sup>26,32-35</sup>

The results obtained by the DM sub-group analysis of GFAP levels in the intervention group showed an increasing trend of 0.4 ( $-0.3 - 1.3$ ) compared to the control group of 1 ( $-0.5 - 7.9$ ) and statistically not significantly different ( $p > 0.05$ ). Unlike the case with the non-DM subgroup in the intervention group which showed a decreasing trend of  $-0.2$  ( $-3.5 - 3.4$ ) compared to the control group where there was an increasing trend of 0.8 ( $-0.5 - 4.9$ ) and not statistically significant ( $p > 0.05$ ). This occurred because, in patients with hyperglycemia, it can provide nerve degeneration through oxidative stress. Metabolic and oxidative factors often cause rapid changes in glial cells. A key indicator of this response was an increased synthesis of GFAP, which is an astrocytic marker. The event was evidenced by the study of Baydas *et al.* (2003) who conducted a study on 40 experimental animals divided into three groups. The first group was injected with STZ, the second group was injected with STZ + melatonin, and the last group was the control group. The results showed that the STZ-induced group caused glial reactivity, while the STZ + melatonin-injected group decreased the GFAP reactivity.<sup>36</sup>

Research on the effect of giving protein, phosphatidylcholine, phosphatidylserine, and inulin on markers of brain damage such as GFAP is still minimal. In this study, the intervention was administered orally or in the form of powdered enteral formula with protein,



phosphatidylcholine, phosphatidylserine, and inulin. Efficiently, phosphatidylcholine and phosphatidylserine are almost entirely absorbed, which then spreads throughout the body across the blood-brain barrier and into the central nervous system. Inulin is easily dissolved in water and difficult to hydrolyze by enzymes in the digestive tract so that it can reach the large intestine as a whole. Probiotic bacteria will ferment inulin in the intestines and become short-chain fatty acids called SCFA.<sup>10,23,27</sup>

In this study, the intervention gave still affected even though it was not statistically significant ( $p > 0.05$ ), according to research from Ji *et al.* (2018), a high protein diet given earlier can improve motor coordination. Currently, most of the hospitals have implemented facilities such as flexor and elbow extensor training, physiotherapy, for example, teaching good movement patterns and posture. However, this facility will not be optimal if there are patients with severe disabilities and a lack of cooperation between patients and hospital staff. Increasing SOD expression, restoring iNOS expression, and suppressing MDA expression are among the advantages of the early high protein diet. This suggests that oxidative stress can be inhibited if a high-protein diet is given early on so that free radicals and inflammation in the body can be reduced and can improve post-stroke clinical outcomes.<sup>32</sup>

Supported by research by Aquilani *et al.* (2008) which provided supplementation with hyperproteic nutritional formulas (10% protein = 40 grams of protein) in 20 patients for 21 days, it showed that the National Institutes Stroke Scale (NIHSS) scores of patients with protein administration increased on average 4.4 compared to a control group average of 3.0. However, there was an increase in motor recovery of the paretic arms and legs which were found to be better able to withstand gravity for 10 seconds (with legs outstretched) in the intervention group. The improvement in the performance of the extremities against gravity was less seen in the control group patients.<sup>33</sup> In this study, it has a ratio of 1: 2 related to protein administration with research conducted by Aquilani.

In a study conducted by Tykhomyrov *et al.* (2019) who examined the effect of giving CDP-choline or citicoline injections to 33 ischemic stroke patients with GFAP levels who gave citicoline injection of 1000 mg for 14 days, they decreased GFAP levels by 61% with ( $p = <0.01$ ).

CDP-choline can protect astrocytes and neurons, as well as increase angiogenic capacity through downregulation of angiostatin in post-ischemic patients with atrial fibrillation after acute ischemic stroke. Also, CDP-choline can increase cell proliferation, vasculogenesis, and synaptophysin levels and reduce GFAP levels in the peri-infarct area in ischemic stroke. In this study, enteral nutrition was given with a content of 384 phosphatidylcholine/day.<sup>34</sup>

In a study conducted by Kataoka *et al.* (2010) which examined the effect of Soy-PS administration on 78 elderly people with mild cognitive impairment (50-69 years) were randomly selected to consume Soy-PS (100 mg or 300 mg/day) or placebo for 6 months. Administration of Soy-PS orally for 6 months improved memory function, especially delayed memory in the elderly with memory complaints. Administration of Soy-PS was able to improve memory function, especially delayed memory in the elderly with memory complaints. Increasing the memory score is also one of the benefits of giving Soy-PS. The activation of signaling proteins and receptors that are essential for neuronal survival is influenced by phosphatidylserine. Phosphatidylserine also plays a role in signaling processes such as regulating neurotransmitters. In this study, the intervention was given with enteral nutrition containing 96 phosphatidylserines/day for 7 days.<sup>26</sup>

The administration of inulin in Hoffman's study was 8% by injection of inulin in mice which were equivalent to 40 grams of inulin in humans per day. Hoffman's research shows that 8% inulin can increase cecal content, produce more SCFA, increase the number of bacterial enzymes in the cecum, increase systemic metabolism by modulating the gut microbiome, and can reduce the characteristics of brain inflammation in early AD (Alzheimer's Disease) compared to 4% inulin. Hoffman's research also states that 8% is considered the maximum tolerable and beneficial amount for the human organism. In this study, 9 grams of inulin per day were given.<sup>35</sup>

Inulin is a part of prebiotics. Prebiotics is a component of food that cannot be digested by the digestive tract enzymatically, which will then fermented by microbiota in the intestine. Inulin is a substrate that progresses the diversity of beneficial microbiota in the intestine so that the production of SCFAs such as acetate, propionate, and butyrate will increase as a result of anaerobic fermentation. The gut-brain axis is influenced by



SCFA either directly or indirectly. SCFA binds to various receptors to further inhibit histone deacetylation and affect the integrity of the intestinal barrier and intestinal mucosal immunity. The interaction performed by the SCFA on various receptors can induce indirect signaling to the brain by inducing the secretion of intestinal hormones. Systemic inflammation is affected by SCFA by regulating leukin secretion and inducing differentiation of Tregs or T regulatory cells. The blood-brain barrier can be penetrated by the SCFA through the MCT or monocarboxylate transporter and improves the integrity of the blood-brain barrier. SCFA can enhance neurogenesis, function, and homeostasis of nerve cells and improve the morphology and function of glial cells found in the central nervous system.<sup>35,37</sup>

RTPA therapy also appears to contribute to study results. In the study by Davalos *et al.* (2002), 47% of patients were treated with rTPA and given citicoline therapy 1000 mg per 12 hours intravenously for three days, then orally were given 2x500 mg tablets per 12 hours for a total of six weeks. rTPA can rebuild blood flow in the penumbra; therefore it is difficult for citicoline to enhance the performance caused by the effects of thrombolysis. The severity of most stroke patients in Davalos *et al.*'s study was also high so that no penumbra region was susceptible to being saved by citicoline. Consequently, in the subgroup without rTPA, the efficacy of citicoline exhibited better results than the group with rTPA.<sup>24</sup> In this study, 4 patients received rTPA therapy.

Furthermore, it can be caused by patients who have gone home before the 7th day. Although given enteral formula to continue therapy at home, this can cause researchers to be unable to control whether or not the intervention is complete. The drugs received and the presence of comorbidities that concern the improvement of clinical outcome in ischemic stroke patients, because of these factors, a significant reduction in GFAP levels required.

A multicentre study conducted on 4023 ischemic stroke patients who were given protein-energy supplement of 62.5 g / day for 6-7 months in 125 hospitals and 15 countries showed that routine oral protein energy supplementation of a usual hospital diet did not improve outcomes in patients admitted with recent stroke.<sup>38</sup> A study by Sabin *et al.* (2013) giving citicoline to 347 ischemic stroke subjects (1g / day for 12 months) showed no significant difference ( $p = 0.186$ ).<sup>39</sup>

Copyright © 2021; Jurnal Gizi Indonesia (The Indonesian Journal of Nutrition), Volume 9 (2), 2021  
e-ISSN : 2338-3119, p-ISSN: 1858-4942

Supported by Clark's study that gave citicoline to 453 ischemic stroke subjects (1000 mg 2x / day for 12 weeks) showed no significant difference ( $p>0.05$ ).<sup>40</sup> A study conducted by Manor *et al.* (2013) regarding the administration of phosphatidylserine in 30 elderly with memory complaints (300 mg/day for 10 weeks) showed no significant difference in focused attention, sustained attention, visuospatial learning, spatial short-term memory ( $p>0.05$ ).<sup>41</sup> The study by Tuncay *et al.* (2018) who performed Enteral Formula with Probiotic Content (EFPC) intervention in 23 neuro-critical care patients for 21 days was associated with more frequent dosing of subjects showing no significant difference.<sup>42</sup>

The results of this study emphasized that enteral formula containing protein, phosphatidylcholine, phosphatidylserine, and inulin had a good effect on GFAP levels, as evidenced by changes ( $\Delta$ ) in serum GFAP levels in the intervention group which decreased  $-0.07 \pm 2.26$  compared to the control group which increased  $2.13 \pm 2.84$  although it was not statistically significant ( $p>0.05$ ).

In General Linear Model (GLM), it shows that there is no significant difference in ( $\Delta$ ) GFAP levels were controlled by age variable ( $p>0,05$ ). This may be due to the lack of research samples. During the study, there was a COVID-19 pandemic which made patients tend to hesitate or fear to have themselves examined at Dr. Kariadi. Remembering Dr. Kariadi is a referral hospital in Semarang.

The limitations of this study were the shortage of sample, length of time, and dose of administration. The advantage of this study is to provide enteral nutrition therapy to stroke patients by examining brain damage markers (GFAP) because this study is still very limited, so it can add to the literature for other researchers.

## CONCLUSIONS

The addition of 15 g protein, 128 mg phosphatidylcholine, 32 mg phosphatidylserine, and 9 g inulin given for seven days had no significant effect on GFAP levels.

## ACKNOWLEDGMENT

Thank you to Dr. Kariadi Hospital, who has permitted researchers so that this research can run well, and thank you to Diponegoro University which has provided this research grant.



## REFERENCES

1. Liu G, Geng J. Glial fibrillary acidic protein as a prognostic marker of acute ischemic stroke. *Hum Exp Toxicol*. 2018;37(10):1048–53.
2. Surjawan Y, As'ad S, Ranakusuma TAS, Wijaya A. The different patterns of blood S100b protein and GFAP concentrations in ischemic stroke. *Med J Indones*. 2013;22(4):215–20.
3. Petzold A. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. *Brain Res [Internet]*. 2015;1600:17–31. Available from: <http://dx.doi.org/10.1016/j.brainres.2014.12.027>
4. Middeldorp J, Hol EM. GFAP in health and disease. *Prog Neurobiol [Internet]*. 2011;93(3):421–43. Available from: <http://dx.doi.org/10.1016/j.pneurobio.2011.01.005>
5. Žurek J, Fedora M. The usefulness of S100B, NSE, GFAP, NF-H, secretogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury. *Acta Neurochir (Wien)*. 2012;154(1):93–103.
6. Dvorak F, Haberer I, Sitzler M, Foerch C. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral hemorrhage and ischaemic stroke. *Cerebrovasc Dis*. 2009;27(1):37–41.
7. Puspitasari V, Gunawan PY, Wiradarma HD, Hartoyo V. Glial fibrillary acidic protein serum level as a predictor of clinical outcome in ischemic stroke. *Open Access Maced J Med Sci*. 2019;7(9):1471–4.
8. Raisa N, Sujuti H, Purnomo H, Rahayu M, Dalhar M. the Influence of Sampling Time To Serum Glial Fibrillary Acidic Protein (Gfap) Levels in Acute Stroke. *MNJ (Malang Neurol Journal)*. 2019;5(1):30–3.
9. Presley B. Penatalaksanaan Farmakologi Stroke Iskemik Akut. *Bul Rasional [Internet]*. 2013;12(1):6–8. Available from: [http://repository.ubaya.ac.id/21378/1/Rasional Vol 12 No 1.pdf](http://repository.ubaya.ac.id/21378/1/Rasional%20Vol%2012%20No%201.pdf)
10. Glade MJ, Smith K. Phosphatidylserine and the human brain. 2015;31(6):781–6. Available from: <http://dx.doi.org/10.1016/j.nut.2014.10.014>
11. Overgaard K. The effects of citicoline on acute ischemic stroke: A review. *J Stroke Cerebrovasc Dis [Internet]*. 2014;23(7):1764–9. Available from: <http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2014.01.020>
12. Sahota P, Savitz SI. Investigational Therapies for Ischemic Stroke: Neuroprotection and Neuro recovery. *Neurotherapeutics*. 2011;8(3):434–51.
13. Kato-Kataoka A, Sakai M, Ebina R, Nonaka C, Asano T, Miyamori T. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. *J Clin Biochem Nutr*. 2010;47(3):246–55.
14. Anderson H, Luhovyy B, Akhavan T, Panahi S. Enteral formula proteins in the regulation of body weight, satiety, food intake, and glycemia. *Nestle Nutr Work Ser Pediatr Progr*. 2011;67:147–59.
15. Lien DTK, Nhung BT, Khan NC, Hop LT, Nga NTQ, Hung NT, et al. Impact of enteral formula consumption on performance and health of primary school children in rural Vietnam. *Asia Pac J Clin Nutr*. 2009;18(3):326–34.
16. Patel S. Functional food relevance of whey protein: A review of recent findings and scopes ahead. *J Funct Foods*. 2015;19:308–19.
17. Mitchell CJ, McGregor RA, D'Souza RF, Thorstensen EB, Markworth JF, Fanning AC, et al. Consumption of enteral formula protein or whey protein results in a similar increase in muscle protein synthesis in middle-aged men. *Nutrients*. 2015;7(10):8685–99.
18. Colonic T, Homeostasis C, Smith PM, Howitt MR, Panikov N, Michaud M, et al. Reports 1000. 2013;(August):569–74.
19. Liu TW, Cephas KD, Holscher HD, Kerr KR, Mangian HF, Tappenden KA, et al. Nondigestible fructans alter gastrointestinal barrier function, gene expression, histomorphology, and the microbiota profiles of diet-induced obese C57BL/6J Mice. *J Nutr*. 2016;146(5):949–56.
20. Chunchai T, Keawtep P, Arinno A, Saiyasit N, Prus D, Apaijai N, et al. N-



- acetyl cysteine, inulin and the two as a combined therapy ameliorate cognitive decline in testosterone-deprived rats. *Aging (Albany NY)*. 2019;11(11):3445–62.
21. Bansal V, Costantini T, Ryu SY, Peterson C, Loomis W, Putnam J, et al. Stimulating the central nervous system to prevent intestinal dysfunction after traumatic brain injury. *J Trauma - Inj Infect Crit Care*. 2010;68(5):1059–63.
22. BPOM RI. Peraturan Kepala Badan Pengawas Obat dan Makanan Republik Indonesia Nomor 9 Tahun 2016 tentang Acuan Label Gizi. Badan Pengawas Obat dan Makanan Republik Indones. 2016;1–28.
23. Wahyudi R, Hasmono D, Fitriana R, Armal K. Injected Citicoline Improves Impairment and Disability During Acute Phase Treatment in Ischemic Stroke Patients. *Folia Medica Indones*. 2016;51(4):245.
24. Dávalos A, Castillo J, Álvarez-Sabín J, Secades JJ, Mercadal J, López S, et al. Oral citicoline in acute ischemic stroke: An individual patient data pooling analysis of clinical trials. *Stroke*. 2002;33(12):2850–7.
25. Wirth R, Smoliner C, Jäger M, Warnecke T, Leischner AH, Dziewas R, et al. Guideline clinical nutrition in patients with stroke. *Exp Transl Stroke Med*. 2013;5(1):1–11.
26. A. K-K, M. S, R. E, C. N, T. A, T. M. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. *J Clin Biochem Nutr* [Internet]. 2010;47(3):246–55. Available from: [http://linker.worldcat.org/?rft.institution\\_id=129635&spage=246&pkgName=UKP MC&issn=0912-0009&linkclass=to\\_article&jKey=897&issue=3&provider=NLM&date=2010-11&aulast=Kato-Kataoka+A.%3B+Sakai+M.%3B+Ebina+R.%3B+Nonaka+C.%3B+Asano+T.%3B+Miyamori+T.&atitle=Soyb](http://linker.worldcat.org/?rft.institution_id=129635&spage=246&pkgName=UKP MC&issn=0912-0009&linkclass=to_article&jKey=897&issue=3&provider=NLM&date=2010-11&aulast=Kato-Kataoka+A.%3B+Sakai+M.%3B+Ebina+R.%3B+Nonaka+C.%3B+Asano+T.%3B+Miyamori+T.&atitle=Soyb)
27. Setiarto RHB, Widhyastuti N, Saskiawan I, Safitri RM. Pengaruh Variasi Konsentrasi Inulin Pada Proses Fermentasi Oleh *Lactobacillus acidophilus*, *Lactobacillus bulgaricus* Dan *Streptococcus thermophilus*. *Biopropal Ind*. 2016;8(June):1–17.
28. Zang J, Liu AX, Qi L. The cytological mechanism and effects of hypertensive cerebral hemorrhage treatment by citicoline on serum GFAP and copeptin level. *Eur J Inflamm*. 2019;17.
29. Andriani A, Prijanti AR, Mudjihartini N, Jusman SWA. Dampak Hipoksia Sistemik terhadap Malondialdehid, Glial Fibrillary Acidic Protein dan Aktivitas Asetilkolin Esterase Otak Tikus. *eJournal Kedokt Indones*. 2016;4(2).
30. Ren C, Kobeissy F, Alawieh A, Li N, Li N, Zibara K, et al. Assessment of serum UCH-L1 and GFAP in acute stroke patients. *Sci Rep*. 2016;14(6):1–9.
31. Lotosh NG, Savel'Eva EK, Selishcheva AA, Savel'Ev S V. Autoantibodies to neuron-specific proteins S100, GFAP, MBP, and NGF in the serum of rats with streptozotocin-induced diabetes. *Bull Exp Biol Med*. 2013;155(1):48–51.
32. Ji M, Li S, Dong Q, Hu W. Impact of an early high-protein diet on neurofunctional recovery in rats with ischemic stroke. *Med Sci Monit*. 2018;24:2235–43.
33. Aquilani R, Scocchi M, Iadarola P, Franciscone P, Verri M, Boschi F, et al. Protein supplementation may enhance the spontaneous recovery of neurological alterations in patients with ischaemic stroke. *Clin Rehabil*. 2008;22(12):1042–50.
34. Tykhomyrov AA, Kushnir YS, Nedzvetsky VS, Grinenko T V., Kuryata O V. Citicoline affects serum angiotatin and neuro specific protein levels in patients with atrial fibrillation and ischemic stroke. *Ukr Biochem J*. 2019;91(5):34–45.
35. Hoffman JD, Yancello LM, Chlipala G, Hammond TC, McCulloch SD, Parikh I, et al. Dietary inulin alters the gut microbiome, enhances systemic metabolism, and reduces neuroinflammation in an APOE4 mouse model. *PLoS One*. 2019;14(8):1–22.
36. Baydas G, Reiter RJ, Yasar A, Tuzcu M, Akdemir I, Nedzvetskii VS. Melatonin reduces glial reactivity in the hippocampus, cortex, and cerebellum of streptozotocin-induced diabetic rats. *Free*



37. Radic Biol Med. 2003;35(7):797–804.
38. Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. *Front Endocrinol (Lausanne)*. 2020;11(January):1–14.
39. Dennis M. Routine oral nutritional supplementation for stroke patients in hospital (FOOD): A multicentre randomized controlled trial. *Lancet*. 2005;365(9461):755–63.
40. Alvarez-Sabín J, Ortega G, Jacas C, Santamarina E, Maisterra O, Ribo M, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. *Cerebrovasc Dis*. 2013;35(2):146–54.
41. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. *Neurology*. 2001;57(9):1595–602.
42. Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, et al. Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: A double-blind placebo-controlled trial followed by an open-label extension. *Eur Psychiatry*. 2013;28(6):386–91.
43. Tuncay P, Arpacı F, Doganay M, Erdem D, Sahna A, Ergun H, et al. Use of standard enteral formula versus enteric formula with prebiotic content in nutrition therapy: A randomized controlled study among neuro-critical care patients. *Clin Nutr ESPEN* [Internet]. 2018;25:26–36. Available from: <https://doi.org/10.1016/j.clnesp.2018.03.123>



# The effect of addition protein, phosphatidylcholine, phosphatidylserine, and inulin on GFAP levels of acute ischemic stroke patients at Dr. Kariadi Hospital, Semarang

## ORIGINALITY REPORT

12%

SIMILARITY INDEX

7%

INTERNET SOURCES

9%

PUBLICATIONS

1%

STUDENT PAPERS

## PRIMARY SOURCES

1	<a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a> Internet Source	1%
2	Vishal Bansal, Todd Costantini, Seok Yong Ryu, Carrie Peterson et al. "Stimulating the Central Nervous System to Prevent Intestinal Dysfunction After Traumatic Brain Injury", Journal of Trauma: Injury, Infection & Critical Care, 2010 Publication	1%
3	"Bioactive Molecules in Food", Springer Science and Business Media LLC, 2019 Publication	1%
4	<a href="http://www.myfoodresearch.com">www.myfoodresearch.com</a> Internet Source	<1%
5	<a href="http://www.hartfordign.org">www.hartfordign.org</a> Internet Source	<1%
6	<a href="http://www.science.gov">www.science.gov</a> Internet Source	<1%



7	Desiyana Evlyn, Ferdy Kurniawan Cayami, Hardian, Annastasia Ediaty, Agustini Utari, Tri Indah Winarni. "Attitudes of Indonesian health science undergraduates toward sexuality in individuals with intellectual disabilities", Research in Developmental Disabilities, 2021 Publication	<1 %
8	<a href="https://repository.unmul.ac.id">repository.unmul.ac.id</a> Internet Source	<1 %
9	<a href="https://publikationen.ub.uni-frankfurt.de">publikationen.ub.uni-frankfurt.de</a> Internet Source	<1 %
10	"Microbiome-Gut-Brain Axis", Springer Science and Business Media LLC, 2022 Publication	<1 %
11	<a href="https://pdfs.semanticscholar.org">pdfs.semanticscholar.org</a> Internet Source	<1 %
12	<a href="https://www.mdpi.com">www.mdpi.com</a> Internet Source	<1 %
13	V.S. Nedzvetskii, G. Baydas, S.V. Kirichenko. "P32 MELATONIN REDUCES ASTROGLIOSIS IN THE HIPPOCAMPUS AND CORTEX AND COGNITIVE DEFICITS OF STREPTOZOTOCIN-INDUCED DIABETIC RATS.", Behavioural Pharmacology, 2006 Publication	<1 %
14	<a href="https://www.e-journal.unair.ac.id">www.e-journal.unair.ac.id</a> Internet Source	



<1 %

15

[www.laspineinstitute.com](http://www.laspineinstitute.com)

Internet Source

<1 %

16

Jian Zhang, Chun-Hua Zhang, Xiao-Li Lin, Qiang Zhang, Jing Wang, Sheng-Liang Shi. "Serum glial fibrillary acidic protein as a biomarker for differentiating intracerebral hemorrhage and ischemic stroke in patients with symptoms of acute stroke: a systematic review and meta-analysis", Neurological Sciences, 2013

Publication

<1 %

17

Submitted to Universitas Negeri Semarang

Student Paper

<1 %

18

[academic.oup.com](http://academic.oup.com)

Internet Source

<1 %

19

[doc-pak.undip.ac.id](http://doc-pak.undip.ac.id)

Internet Source

<1 %

20

Overgaard, Karsten. "The Effects of Citicoline on Acute Ischemic Stroke: A Review", Journal of Stroke and Cerebrovascular Diseases, 2014.

Publication

<1 %

21

[www.id-press.eu](http://www.id-press.eu)

Internet Source

<1 %



22	Advances in Experimental Medicine and Biology, 2014. Publication	<1 %
23	hundesportverein-duengenheim.de Internet Source	<1 %
24	synapse.koreamed.org Internet Source	<1 %
25	N. G. Lotosh, E. K. Savel'eva, A. A. Selishcheva, S. V. Savel'ev. "Autoantibodies to Neuron-Specific Proteins S100, GFAP, MBP and NGF in the Serum of Rats with Streptozotocin-Induced Diabetes", Bulletin of Experimental Biology and Medicine, 2013 Publication	<1 %
26	scholars.latrobe.edu.au Internet Source	<1 %
27	Nicole Arnold, Thomas Girke, Suhas Sureshchandra, Ilhem Messaoudi. "Acute Simian Varicella Virus Infection Causes Robust and Sustained Changes in Gene Expression in the Sensory Ganglia", Journal of Virology, 2016 Publication	<1 %
28	mnj.ub.ac.id Internet Source	<1 %
29	www.scribd.com Internet Source	<1 %



30	<a href="http://d-nb.info">d-nb.info</a> Internet Source	<1 %
31	<a href="http://stroke.ahajournals.org">stroke.ahajournals.org</a> Internet Source	<1 %
32	<a href="http://www.jpma.org.pk">www.jpma.org.pk</a> Internet Source	<1 %
33	<a href="http://www.mfbioscience.com">www.mfbioscience.com</a> Internet Source	<1 %
34	Chairil Amin Batubara, Listra Isabela Barus, Aida Fithrie. "Effect of Oral Nutritional Supplementation on National Institute of Health Stroke Scale in Acute Ischemic Stroke", Open Access Macedonian Journal of Medical Sciences, 2022 Publication	<1 %
35	Jiri Polivka, Jiri Polivka, Kristyna Krakorova, Marek Peterka, Ondrej Topolcan. "Current status of biomarker research in neurology", EPMA Journal, 2016 Publication	<1 %
36	Robert Brunkhorst, Waltraud Pfeilschifter, Christian Foerch. "Astroglial Proteins as Diagnostic Markers of Acute Intracerebral Hemorrhage—Pathophysiological Background and Clinical Findings", Translational Stroke Research, 2010 Publication	<1 %



37

Rui Chen, Jiangwei Shi, Qingsheng Yin, Xiaojin Li, Yanyuan Sheng, Juan Han, Pengwei Zhuang, Yanjun Zhang. "Morphological and Pathological Characteristics of Brain in Diabetic Encephalopathy", Journal of Alzheimer's Disease, 2018

Publication

---

&lt;1 %

38

Tang, Sung-Chun, Shin-Joe Yeh, Li-Kai Tsai, Chaur-Jong Hu, Li-Ming Lien, Giia-Sheun Peng, Wei-Shiung Yang, Hung-Yi Chiou, and Jiann-Shing Jeng. "Association between plasma levels of hyaluronic acid and functional outcome in acute stroke patients", Journal of Neuroinflammation, 2014.

Publication

---

&lt;1 %

39

Wanda JE Bemelmans. "Impact of Mediterranean diet education versus posted leaflet on dietary habits and serum cholesterol in a high risk population for cardiovascular disease", Public Health Nutrition, 09/2000

Publication

---

&lt;1 %

40

Xiaofang Liu, Jie Cui, Kailiang Leng, Changhu Xue, Zhaojie Li, Yong Xue, Yuming Wang. "Docosahexaenoic acid-enriched phospholipids exhibit superior effects on obesity-related metabolic disorders to egg yolk phospholipids and soybean

&lt;1 %



# phospholipids in mice", European Journal of Lipid Science and Technology, 2016

Publication

41

[core.ac.uk](http://core.ac.uk)

Internet Source

<1 %

42

[digitalcommons.lsu.edu](http://digitalcommons.lsu.edu)

Internet Source

<1 %

43

[eprints.undip.ac.id](http://eprints.undip.ac.id)

Internet Source

<1 %

44

[link.springer.com](http://link.springer.com)

Internet Source

<1 %

45

[research.rug.nl](http://research.rug.nl)

Internet Source

<1 %

46

[www.aor.ca](http://www.aor.ca)

Internet Source

<1 %

47

[www.karger.com](http://www.karger.com)

Internet Source

<1 %

48

[www.mif-ua.com](http://www.mif-ua.com)

Internet Source

<1 %

49

C. D'Uva. "Protein energy supplementation of usual hospital diet did not improve outcomes in inpatients with recent stroke", Evidence-Based Nursing, 2005

Publication

<1 %



50

Xiao-yan ZHANG, Yu ZHANG, Ying-jie SUN, Hong-na FAN, Yu-gang DIAO. "Analgesic efficacy of Transverse thoracic muscle plane block (modified approach) in off-pump coronary artery bypass grafting : A retrospective cohort study", Research Square Platform LLC, 2022

Publication

&lt;1 %

51

"Neuroprotective Therapy for Stroke and Ischemic Disease", Springer Science and Business Media LLC, 2017

Publication

&lt;1 %

52

Ygor Parladore Silva, Andressa Bernardi, Rudimar Luiz Frozza. "The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication", Frontiers in Endocrinology, 2020

Publication

&lt;1 %

Exclude quotes Off

Exclude bibliography On

Exclude matches Off



# The effect of addition protein, phosphatidylcholine, phosphatidylserine, and inulin on GFAP levels of acute ischemic stroke patients at Dr. Kariadi Hospital, Semarang

## GRADEMARK REPORT

FINAL GRADE

/0

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5

PAGE 6

PAGE 7

PAGE 8

PAGE 9

PAGE 10

PAGE 11

PAGE 12

PAGE 13

PAGE 14